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The Influence of Amyloid-Beta, a Major Pathological Marker in Alzheimer's
Disease, on Molecular Cognitive Processes of APP+PS1 Transgenic Mice
Chad Anthony Dickey
ABSTRACT
Alzheimer’s disease (AD) is characterized by anterograde amnesia
followed by a progressive decline in cognitive function. Post mortem examination
of forebrain tissue from sufferers reveals the presence of extra-cellular amyloidbeta plaques, intracellular neurofibrillary tangles, activation of glial cells and
massive neuron loss. Transgenic mice expressing mutated forms of the amyloid
precursor protein (APP) and presenilin-1 (PS1) genes develop neuritic amyloid
plaques, glial cell activation and memory deficits, without the formation of
intracellular tangles and neurodegeneration.
The mechanisms by which these transgenic mice develop mnemonic
deficiencies are unclear. Gene expression of aged memory-deficient APP+PS1
mice compared with non-transgenic littermates measured by microarray and
subsequent quantitative real-time PCR (qRT-PCR) analysis revealed 6 inducible
immediate-early genes (IEGs) and 5 other more stably expressed plasticityrelated genes (PRGs) that were significantly down-regulated in amyloidcontaining hippocampus, but not down-regulated in amyloid-free cerebellum.
Other genes linked to memory remained stably expressed in both regions.
Analysis of forebrain AD tissue revealed that all genes measured were downv

regulated presumably due to neurodegeneration, while the amyloid-free region
maintained stable expression. IEG expression in APP+PS1 mice was sensitive to
lower levels of amyloid. However, only in the presence of a substantially larger
amyloid burden, when memory deficits reliably persist, were both PRGs and
IEGs down-regulated. Importantly, we found that IEG expression was decreased
in APP+PS1 mice following exposure to a novel environment, indicating that the
induction of these IEGs was impaired, rather than the basal expression of resting
mice.
Na+/K+ ATPase, an enzyme critical for the maintenance of membrane potential,
was identified as a down-regulated PRG. We found that activity of this enzyme
was both impaired in the hippocampi of APP+PS1 mice and specifically inhibited
by high concentrations of amyloid-beta. Na+/K+ ATPase immunostaining
revealed decreased protein in the area surrounding the amyloid plaque, where
dystrophic neurites were visible, indicating amyloid may disrupt ionic gradients
resulting in neuritic dystrophia. These findings suggest that amyloid accumulation
may result in the impairment of IEG induction and disruption of the Na+/K+
ATPase, possibly eliciting the memory loss developed in APP+PS1 mice.

vi

INTRODUCTION
ALZHEIMER’S DISEASE.
Memory loss is the primary and most deleterious symptom of AD.
Sufferers initially lose their cognitive abilities followed slowly by autonomic
deterioration. AD pathology is characterized by both the extra-cellular cerebral
accumulation of Aβ 1-42 (Hardy, 1997) and the aggregation of intracellular
tangles of a hyperphosphorylated form of the tubulin-associated protein, tau (τ)
(Mattson, 1997). The AD brain is not only characterized by these plaques and
tangles, but also by neuronal and synaptic loss, as evidenced by the downregulation of cytoskeletal- and exocytotic-associated proteins. The severity of AD
can then be determined based on this collective pathology (Masliah et al.,
2001;Mukaetova-Ladinska et al., 2000;Benowitz and Routtenberg, 1997;Yao and
Coleman, 1998;Callahan et al., 2002).
Amyloid precursor protein (APP) is processed post-translationally by
several proteases known as α-, ß- and γ-secretase. Agonists for the α secretase
and inhibitors of both the ß- and γ-secretases have shown promise for use in AD
therapy. The α-secretase cleaves membrane-bound APP within the Aß 1-42
amino acid site, yielding peptide products that lack any aggregative properties.
ß-secretase (BACE1) acts closer to the N-terminal of APP leaving a longer
1

fragment for γ-secretase to cleave which results in production of the deleterious
amyloidogenic Aß 1-42 molecule. The activity of the γ-secretase on the remaining
membrane-bound portion of APP following ß-secretase cleavage can yield either
the 1-42 Aβ fragment with fibrillogenic properties or a much less sticky 1-40
peptide product (Selkoe, 2001;Dewachter and Van Leuven, 2002).
Whether the 1-40 or 1-42 peptide is produced can be largely dependent
upon polymorphisms in the presenilin-1 and -2 (PS1 & PS2, respectively) genes
which greatly influence the activity of the γ-secretase. In fact, mutations in both
the APP and presenilin genes (denoted as mAPP and mPS1 or mPS2 in
transgenic models) can influence amyloid plaque formation causing dramatic
effects on the proclivity of individuals to develop an early-onset form of AD. APP
mutations can lead to increased amyloid pathology by favoring cleavage of the
APP N-terminal fragment by ß- or γ-secretase rather than the α-secretase (Citron
et al., 1997) or by increasing the aggregative properties of the 1-42 peptide itself
(Wisniewski et al., 1991). Mutations in PS1 or PS2 leading to modified γsecretase activity can result in more rapid production of Aß 1-42 (Selkoe, 2001).
In addition to the neurodegenerative effects of amyloid accretion, other
adverse consequences of the cerebral deposition of Aβ peptide include
dysregulation of Ca2+ signaling, mitochondrial damage, free radical production
(Mattson, 1997;Mattson, 2002) and recruitment of both pro-inflammatory
components and glial cells (Roses, 2000). Accumulating evidence suggests that
Aβ precipitates the cascade of pathogenic events leading to the massive
neurological dysfunction and dementia characteristic of AD (for review see Hardy
2

and Selkoe, 2002). One example of this evidence is that Aβ, through interaction
with α7 nicotinic receptors (Dineley et al., 2001), initiates the mitogen activated
protein kinase (MAPK) cascade leading to its over-activation and eventual
dysregulation. Downstream targets of the MAPK cascade include tau (Arendt,
2001) and several immediate early genes important for long-term potentiation
and memory formation. As more evidence becomes available, a clearer
understanding of the relationship between the various pathological features of
AD and the best strategy for its prevention will become more apparent.
Aside from the involvement of the APP and presenilin genes in AD
progression, the normal role that these genes play in brain function has only
been clearly defined for presenilin. PS1 proteins are associated with the synaptic
membrane and weave across it like stitches through fabric. This protein is then
activated by proteolysis into two subunits which leads to its ability to cleave other
membrane-associated proteins, including APP and notch (neurite outgrowthpromoting cell surface glycoprotein), a cell adhesion molecule involved in
neuronal development and the fate determination of other stem cell types
throughout life (Milner and Bigas, 1999;Artavanis-Tsakonas et al., 1995). The
only progress made so far towards identifying the function of APP has been that
it is a ubiquitous membrane-bound phosphoprotein. Several hypotheses have
been presented for its role, but none of these have been generally accepted (da
Cruz e Silva EF and da Cruz e Silva OA, 2003).
Another gene that is critically linked to the onset of AD is ApoE, a protein
that is produced by astrocytes and escorts low-density lipoprotein (LDL) through
3

aqueous environments, making it an essential component of the cholesterol
transport system. There are three alleles of this gene (ε2, ε3, and ε4), which is
located on chromosome 19, and it has been demonstrated that ApoE ε4 is the
strongest predictor of late-onset AD (after 60 years of age). Epidemiologic
studies have revealed that individuals who express the ε4 allele have a greater
occurrence of late-onset AD compared to those of the more common ε3 allele,
while those carrying the ε2 allele are protected from AD (Wahrle and Holtzman,
2003). Many putative explanations for the action of ApoE on the neuropathology
of AD exist (for review see Laws et al., 2003). For example, there is evidence
that ε4 out-competes Aβ for the brain’s protective clearance machinery, allowing
more plaque-forming peptide to aggregate (St George-Hyslop, 2000). In addition,
it has been demonstrated that ApoE ε4 has poor membrane repair properties
(Yang et al., 1997), perhaps indicative of why hippocampal atrophy in AD
patients with the ApoE ε4 allele is more severe (Lehtovirta et al., 1995).
The development of transgenic and knockout mice has proven critical to
the understanding of AD and recent developments have lead to the identification
of several interesting therapeutic targets, including BACE1 (Ohno et al., 2004)
and the γ secretase (Eriksen et al., 2003). However, to identify these targets,
mice with pathological similarities to that of AD patients had to be generated.
Mice transgenic for the mutant forms of the human APP (Hsiao et al., 1996) and
PS1 (Duff et al., 1996) genes were generated and our group developed a viable
doubly transgenic mouse model that expresses both. These APP+PS1 mice
exhibit accelerated amyloid pathology, microglial activation, astrocyte
4

proliferation, neuritic dystrophia and an impaired cognitive phenotype (Holcomb
et al., 1998;Gordon et al., 2002).Over the past four years, we have demonstrated
that these mice develop the hippocampal and cortical Aβ plaques similar to those
found in the AD brain, and despite the lack of the intracellular fibrillary tangles
and neuronal degeneration, they do exhibit memory deficits, thereby providing a
good model for the study of amyloid-associated memory loss (Gordon et al.,
2001;Holcomb et al., 1999;Morgan et al., 2000;Dickey et al., 2001;Jantzen et al.,
2002).

SYNAPTIC PLASTICITY & LTP.
The memory deficits exhibited by the APP+PS1 mice provide a potential
utility in uncovering mechanisms of memory dysfunction. Following the
application of a tetanic burst of stimulation in the hippocampus, synaptic efficacy
is greatly increased for as long as several weeks, a phenomenon called longterm potentiation (LTP). LTP demonstrates that synaptic connectivity of
hippocampal neurons of the perforant, mossy fiber and Schaffer collateral
pathways in the cornu ammonis layers 1 and 3 (CA1 and CA3) can be modified
structurally and electrically following a burst of high frequency stimulation
(Winder and Schramm, 2001;Zola-Morgan et al., 1986;Tsien et al., 1996;Malenka
and Nicoll, 1999;Shapiro, 2001). This event results in the activation of N-methylD-aspartate receptors (NMDAR), allowing the second messenger ion, Ca2+, into
the cell. This is an associative process requiring depolarization of the synaptic
membrane via activation of aminomethyl-phosphonic acid receptors (AMPAR)
5

which dislodges the Mg2+ ion blocking the NMDAR pore and the binding of extracellular glutamate to open the ligand-gated NMDAR calcium channel.
Modification of the pre-synaptic cell is also required for LTP and this process
seems to be induced by a retrograde messenger released from the post-synaptic
neuron, such as nitric oxide (NO; Kandel et al., 2000).
The LTP phenomenon is thought to result from changes in the morphology
and receptor properties of synapses that are dependent on Ca2+ activated
mechanisms in the cell. One mechanism of the modulatory nature of Ca2+ may
be attributed to the activation of Ca2+/calmodulin kinase II α (CaMKIIα, the
catalytic subunit of CaMKII), as demonstrated both by the inability of neurons to
induce LTP when CaMKIIα is specifically inhibited (Perkel et al., 1990) and the
failure of targeted CaMKII knockouts to elicit LTP (Silva et al., 1992). This
enzyme seems essential for the initiation (Otmakhov et al., 1997) of LTP, which
can persist from hours to weeks. The discrepancy in the duration of LTP is not
understood, although the transition from induction to maintenance seems critical.
One hypothesis for the ability of LTP to be maintained is that of the silent
synapse which proposes that post-synaptically silent neuronal junctions can
become activated either by recruitment of new AMPARs to the membrane or by
the spillover of glutamate onto nearby NMDAR synapses (Winder and Schramm,
2001). Currently there are two accepted phases of LTP, aptly named the early
(within the first 30 minutes of stimulation) and late (beginning 30 minutes after
stimulation) LTP phases. What distinguishes the two from each other is the
requirement of de novo protein synthesis in the late phase (Bolshakov et al.,
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1997;Ma et al., 1999). A proposed synthesis-independent intermediate phase
has also been described that requires the activation of protein kinase A (PKA)
and its modulation of several key signal transduction cascades (Nayak et al.,
1998). Early phase LTP, which has been functionally linked to short-term
memory, requires only NMDAR and protein kinase C (PKC) activation (Huang et
al., 1996), two effects well upstream of gene transcription. When an intense late
phase stimulating current such as maximal electro-convulsive seizure (MECS,
stimulates neurons in a similar way as LTP, but more reproducibly) is
administered, rapid induction of a group of genes known as immediate early
genes (IEGs, so named because they do not require new protein synthesis for
transcription) ensues (Cole et al., 1990;Lyford et al., 1995). The regulated
expression of these genes provides modulatory effects on neuronal structure and
function through manipulation of a network of constitutively expressed proteins,
implicating them in enduring forms of LTP, and therefore long-term memory
formation.
An initial shortcoming of LTP was that it required a very intense induction
stimulus (several short successive applications of ~100Hz) well outside of the
physiological range (Tsukada et al., 1994). However, in 1999, Winder et al.
demonstrated that oscillations emitted by hippocampal neurons during
exploratory behavior called the theta (θ) frequency (3-13Hz) can induce LTP, but
activation of the ERK/MAPK cascade is required (Winder and Schramm,
2001;Bach et al., 1995). Another mechanism that induces synaptic plasticity is
the application of low frequency stimulation (1Hz) for a prolonged period, causing
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long-term depression (LTD; Dudek and Bear, 1992), which results in lowered
excitability of the cell for prolonged periods. Therefore, there are two
mechanisms that can induce synaptic plasticity within the hippocampus, LTP and
LTD, both with opposite effects. Interestingly, a phenomenon known as synaptic
history has been described in which differential phosphorylation of AMPARs
results in different enzymatic specificity, with LTP being correlated with CaMKII
specificity and LTD with PKA specificity (Mayford et al., 1995;Lee et al., 2000).
Still, other forms of NMDAR-independent LTP are found at the CA3 mossy fiber
pathway and also in the cerebellum at the Purkinje-parallel fiber synapse (Winder
et al., 1999). These mechanisms may involve the mitogen activated protein
kinase (MAPK) cascade and other unknown components. In summary, the
activation of post-synaptic neurons can elicit signal transducing mechanisms
(Ca2+, MAPK, etc) that eventually lead to changes in synaptic efficacy through
altered gene expression.

BEHAVIOR.
Recent evidence reveals that several activity-inducible IEGs, along with
other constitutively expressed proteins, are up-regulated in animals exposed to
novel environmental stimuli and tasks that require learning, further supporting the
notion of gene induction mediating memory storage. Different aspects of learning
and memory, such as spatial navigation, location learning, consolidation, and
retrieval, seem to require different expressional patterns of these genes. Animal
models generated with selective expression or disruption of some of the
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constitutively expressed LTP-associated genes have had varying success at
linking LTP to specific types of memory (Tsien et al., 1996;Tang et al., 1999;Silva
et al., 1992;Mansuy et al., 1998;Huang et al., 1996).
The ability to determine defects or improvements in various forms of
memory in these transgenics requires the employment of several well-accepted
training batteries. The Morris water maze is most often used to assess memory
retention. It places a mouse in a pool of opaque water with a small flagged
platform just beneath the surface (Morris, 1984). The mouse’s aversion to
swimming provides the impetus to search for the platform, and once it is found, a
normal mouse should be able to locate it quickly in subsequent trials by
recognizing the flag as a cue. A hippocampal-dependent version of the trial
incorporates the use of visual cues outside of the pool, making this a spatial
navigation task. Another spatial test that removes water as the aversion and
replaces it with an obtrusive noise and bright light is the Barnes maze (Barnes,
1979). Here, animals are placed in an open field with holes surrounding the
perimeter, one of which exits to an escape tunnel. Cognitive abilities are
measured in a similar manner as that of the Morris water maze, either by cuing
the animal with a flag near the escape tunnel opening and measuring errors
made in trials following learning of the flag location or by placing exterior visual
cues around the field without the flag for hippocampal-dependent learning
assessment.
Contextual fear conditioning is another means of measuring memory that
uses an aversive stimulus (normally electric shock) coupled to a sound. The
9

animal eventually learns to “freeze” in response to the sound, preventing it from
receiving an additional shock. Social transmission of food preference (Kogan et
al., 1997) utilizes a tester mouse that is exposed to a food with a particular scent.
This animal is then readmitted to the general population and these other mice are
exposed to food with the same scent used earlier and a new scent. These
animals exhibit learning if they only eat the food that the tester had eaten
because they know that it is safe. One other example is novel object recognition
(Mansuy et al., 1998;Mumby et al., 1996;Myhrer, 1988), in which a mouse is
exposed to two objects for some time. Then, with the addition of a third object,
learning is determined by increased latency with this new object.
Animals such as the GluR1 knockout (KO) mouse (Zamanillo et al., 1999),
the CaMKIIα KO mouse (Silva et al., 1992), and the calcineurin KO mouse
(Mansuy et al., 1998) have demonstrated impaired performance in behavioral
tasks and reduction in LTP phenotype. However, one particular animal overexpressing the NMDAR subunit NR2B exhibited marked increases in both LTP
and behavioral task performance, edifying the possibility of memory being
influenced by NMDAR-dependent LTP (Tang et al., 1999).
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CONSTITUTIVE PROTEIN EXPRESSION.
The properties of several constitutively expressed genes make them
excellent targets for future memory-related studies. Aside from proteins essential
for the basic functions of neurons such as the Na+/K+ ATPase, other key
components of the LTP system of memory formation are neurotransmitter
receptors. The NMDAR is an ionotropic glutamate receptor that also requires
glycine binding as a co-agonist for activation, and is composed of several
heteromeric transmembrane subunits. There are three types of subunits (NR1,
NR2 and NR3), each with a variable number of isoforms designated by a letter
(for example, four isoforms of NR2 include NR2A, NR2B, NR2C and NR2D; CullCandy et al., 2001). Each receptor requires the incorporation of several NR1
subunits and at least one NR2 subunit. NR3 can co-assemble with any NR1/NR2
complex. The NR2 subunit determines the rate of current decay through the
channel and the affinity of the receptor for glutamate, while NR1 determines the
affinity for glycine. NR2A and NR2B elicit a high conductance coupled with a high
affinity for extra-cellular Mg2+, while NR2C and NR2D exhibit the opposite effects
(Cull-Candy et al., 2001). Interestingly, during development NR2B and NR2D are
highly expressed, but as maturation progresses they are replaced with NR2A or
NR2C resulting in a faster rate of current decay. This illustrates a possible
explanation as to how constitutive over-expression of NR2B may result in
memory enhancement (Tang et al., 1999).
As previously noted, AMPARs are also fundamental to the induction of
LTP, providing enough depolarization upon ligand-binding to release the Mg2+ ion
11

that blocks the NMDAR channels. These receptors have several isoforms, each
with varying affinities for glutamate and conductance properties. AMPARs have
even been directly linked to NMDARs via modulatory proteins, allowing crosstalk
between the two channels (Soderling and Derkach, 2000). In AD, AMPARs have
an altered expression, and this may contribute to the associated dementia.
Modulation of plasticity and LTP also involves the presence of “sensors”
on the post-synaptic membrane that can modify synaptic connectivity. One such
protein is a recently described gene product called calsyntenin-1 (CSTN-1), a
transmembrane protein that is specific to post-synaptic dendrites (Vogt et al.,
2001). The cytoskeletal domain binds Ca2+ and undergoes a conformational
change allowing serine proteases in the synaptic cleft to cleave the extra-cellular
portion. The inner subunit may then serve as a Ca2+-signaling molecule that
associates with the spine apparatus at the base of the dendritic shaft, a structure
that has been postulated to be responsible for acquisition of extra membrane
material during synaptogenesis. Another non-IEG protein that seems to be
associated with post-synaptic plasticity is synaptopodin, a molecule that
associates with actin filaments specific to the dendritic tree in the hippocampus,
cortex, and striatum (Mundel et al., 1997). This protein has protein kinase C
(PKC) phosphorylation sites along with a C-terminal 90 amino acid repeat
domain that is common to the PDZ family of proteins (Mundel et al., 1997). Upon
induction following LTP, synatopodin’s linear motif allows side-to-side
arrangement with actin, possibly serving as a mediator between the cytoskeleton
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and other associated proteins, facilitating the subsequent filopodia extension and
retraction properties that PSDs exhibit.
Calmodulin is an intracellular adapter molecule that binds Ca2+ ions
following synaptic transmission. CaMKII is an extremely important neuronspecific serine/threonine kinase that auto-phosphorylates upon binding of the
Ca2+/calmodulin complex. This auto-phosphorylation maintains CaMKII in an
active state even after Ca2+ levels have dissipated. The α subunit of CaMKII is
the catalytic domain of the enzyme and the mRNA for this gene is present at
dendrites, suggesting dendritic translation by the polyribosomes located there
(Steward and Levy, 1982;Steward, 1987). Transgenic mice expressing a
constitutively phosphorylated, and therefore active form of CaMKII are incapable
of expressing θ frequency induced LTP, in fact LTP is converted to LTD in these
animals (Bach et al., 1995;Mayford et al., 1995), rendering them unable to
perform spatial memory dependent tasks. However, these mice are able to learn
from a contextual conditioning trial, lending further credence to the notion of the
significant role intermediate frequencies play in fine-tuning cognitive functions.
Therefore, CaMKII is essential to the induction and maintenance of LTP,
probably attributed to its specificity for countless substrates.
Among these substrates are components of the vesicular exocytosis
system involved in neurotransmitter release (Turner et al., 1999). Briefly,
synapsin 1 attaches vesicles to actin filaments of the axonal cytoskeleton until
phosphorylated. Once released, two proteins on the plasma membrane, syntaxin
and SNAP-25, bind synaptobrevin on the vesicular membrane. The Ca2+ sensor,
13

synaptotagmin, is also located on the vesicle and allows release only if Ca2+ is
bound (Brunger, 2000). Not only are all of these pre-synaptic proteins a substrate
for CaMKII, reiterating its powerful capability to modulate all aspects of
neurotransmitter release and therefore LTP induction, but many post-synaptic
substrates exist as well, such as AMPARs and other receptors, explaining it’s
presence at the PSDs, and demonstrating it’s role in LTP maintenance.

IEG EXPRESSION.
In 1990, Cole et al. created a phage library from MECS stimulated
hippocampal cells, which subsequently lead to the identification of several genes
that seemed to be maximally expressed in response to this LTP-like stimulation
(Cole et al., 1989). Previously, it was demonstrated that ubiquitous transcription
factors such as c-fos (Morgan et al., 1987) and zif268 (Cole et al., 1989) are
induced within a short time of seizure activity and a progressively stronger
stimulus increases the abundance of these IEGs’ mRNAs. The library created by
Cole et al. revealed 15 activity-inducible IEGs, half being transcription factors, the
other half being previously undescribed protein effector genes able to influence
processes such as cell and neurite growth, signal transduction and cytoskeletal
rearrangement (Lanahan and Worley, 1998).
The transcription factors from this group of 15 include mostly ubiquitous
transactivators, such as c-fos, c-jun (which together form AP-1), Nur77 (NGFI-B),
Egr3 and Zif268 (Egr1/NGFI-A), both of the latter being zinc-finger transcriptional
regulators. Both Nur77 and Zif268 are of interest because their mRNA can be
14

induced rapidly by nerve growth factor (NGF). Zif268 is of particular interest
because it’s mRNA is rapidly upregulated both in the hippocampus of rats after
exposure to a novel stimulus (Hall et al., 2000) and in the temporal gyrus of
monkeys following associative learning tasks (Miyashita et al., 1998).
Additionally, viable heterozygous Zif268 knockout mice exhibit both long-term
memory deficits and more rapid decay of LTP than wildtype littermates (Jones et
al., 2001).
The Zif268 promoter contains 2 cAMP responsive elements and therefore
it is assumed that Zif268 transcription is modulated by CREB (Changelian et al.,
1989;Sakamoto et al., 1991). In addition, the MAPK cascade appears to regulate
Zif268 transcription following LTP induction (Davis et al., 2000). Zif268
expression is also tempered by the negative regulator NAB-2, a Zif268-specific
transcriptional repressor protein that is very similar to Stat6 (Abdulkadir et al.,
2001). Therefore, there is both a constitutive (CREB) and inducible (MAPK
cascade) mechanism controlling Zif268 expression, neither of which require any
de novo protein expression, while phosphorylation or dephosphorylation of NAB2 may well be the “switch” that determines when an increase in Zif268 mRNA is
necessary. Zif268 binds the consensus GCG(T/G)GGGCG and can induce the
expression of many cellular factors, including growth factors, cytokines and cell
adhesion molecules, that are essential for the specificity involved with synaptic
plasticity (McCaffrey et al., 2000;Khachigian et al., 1996;Kramer et al.,
1994;Maltzman et al., 1996), properties that warrant the tight regulation of Zif268
expression.
15

Nur77 mRNA, in addition to NGF responsiveness, has also been shown to
be induced by electroconvulsive seizures (Watson and Milbrandt, 1989),
amphetamine administration (Werme et al., 2000;St Hilaire et al., 2003) and
other stress-inducing stimuli (Kovacs and Sawchenko, 1996). It is linked to
inhibitory processes in the dopaminergic system assisting in molecular
mechanisms responsible for fine control of motor function (Drolet et al., 2002).
Nur77 is an orphan thyroid hormone receptor gene that undergoes rapid posttranslational modification and phosphorylation (Fahrner et al., 1990). Additionally,
it binds to DNA consensus sequences similar to that of thyroid hormone receptor,
however, unlike other known members of the thyroid hormone receptor
superfamily, it does not require dimerization in order to bind as a transactivator
(Wilson et al., 1992). The role of Nur77 in memory consolidation has not been
well established, and it remains unclear as to whether this gene is linked to the
learning process or simply the stress elicited by exposure to behavioral
paradigms.
The group of effector IEGs elicited by MECS includes several proteins
with extremely novel characteristics. ß-activin is a transforming growth factor
implicated in neuronal survival that is predominately involved in developmental
processes (Andreasson and Worley, 1995). Rheb, a Ras homologue, is a small
GTP-binding protein that interacts with Raf kinase and seems to integrate growth
factor signals with PKA-signaling cascades specifically in PSDs where both of
these components are activated (Yamagata et al., 1994). Therefore, Rheb may
utilize the hierarchical Ras/Raf cascade to provide highly localized responses to
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many growth factors, since signaling would be restricted to those molecular
layers with activated PKA. Another effector IEG with unique properties is a
member of the pentraxin family called Narp. This protein is thought to be
secreted into the synaptic cleft and promote clustering of pre- and post-synaptic
AMPA receptors (O'Brien et al., 2002), therefore altering plasticity and possibly
establishing the lasting cellular changes necessary for long term memory
formation.
Perhaps the two most intriguing members from this group of IEGs are an
inducible form of a metabotropic glutamate receptor binding protein called Homer
that is found only in activated synapses and the activity-regulated cytoskeletal
associated protein (Arc). Three Homer genes encode Homer-1, 2, and 3 proteins
(Bottai et al., 2002), all modulators of intracellular Ca2+ release. The three Homer
proteins and their isoforms all have an EVH1 domain specific for a proline rich
motif present in metabotropic glutamate receptors (mGluR1 and mGluR5),
ryanodine receptors, IP3 receptors and Shank proteins. This domain links
mGluRs and NMDARs with intracellular Ca2+ stores. Other Homer functions
include regulation of 1) spontaneous activity innate to mGluR1, mGluR5 and K+
channels, 2) directed axonal outgrowth, and 3) dendritic spine morphology. In
particular, the Homer-1 gene gives rise to two IEG products following neuronal
activity, Homer-1a and Ania3, by a novel conversion of an intronic sequence to a
coding exon (Brakeman et al., 1997).
The inducible IEG promoter contains a CRE-site, once again implicating
CREB and the MAPK signaling cascade in LTP-mediated gene induction. These
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IEG products are much smaller than the constitutive Homer-1 gene isoforms,
Homer-1b and 1c, which express a bulky oligomerization domain that seems
critical in preventing their migration across the axon hillock (Bottai et al., 2002).
LTP requires a precise ratio of mGluRs in both the post- and pre-synapse, and
crosstalk between pre-synaptic mGluR5 subunits and post-synaptic NMDARs via
Shank proteins has been demonstrated (Ango et al., 2000). Therefore Homer-1a,
lacking the restrictive multimerization domain, competes with the constitutive
isoforms for binding sites on the C-terminus of newly synthesized metabotropic
glutamate receptors and serves as a “homing” signal for the mGluRs to the presynapse. In fact, the more LTP-inducing stimulus applied to the neuron, the
larger the induction of Homer-1a protein compared with -1b and -1c, resulting in
more mGluRs being targeted to the dendrites. Once the receptors are delivered,
Homer appears to dissociate and be targeted for degradation, attributed to an
ubiquination domain within the IEG product. The presence of specific mGluR
subunits at the pre-synaptic membrane may indicate both their functional
significance as synaptic glutamate sensors and their ability to potentiate
glutamate release in an extra-cellular concentration-dependent manner. These
features, coupled with the ability of mGluR5 to crosstalk with post-synaptic
NMDARs, may demonstrate that LTP is maintained through direct interaction
between the pre- and post-synaptic neuron, underscoring the importance of the
inducible IEG Homer-1a in mediating this positive feedback mechanism.
Arc exhibits the most unique traits of any of the IEGs elucidated from the
MECS library. Following an LTP inducing stimulus, Arc mRNA is rapidly
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upregulated in a matter of 15 minutes within the cell body layer of neurons. By 30
minutes, the mRNA is detected near the dendritic spines. By 1 hour Arc protein is
detected in distal branches of the dendritic trees, demonstrating that Arc is
translated locally on the polyribosomes present at the dendrites (Lyford et al.,
1995). These polyribosomes are dormant except at synapses with activated
mGluRs, therefore local translation at the dendrites is only possible when those
synapses are active (Weiler and Greenough, 1993;Steward and Worley,
2001;Steward, 1995), providing selective expression of transcripts such as Arc.
Other mRNAs that are translated by dendritic ribosomal rosettes are the catalytic
α domain of CaMKII and microtubule-associated protein 2 (MAP2), both of which
are derived from constitutively expressed genes (Wallace et al., 1998). This
leaves Arc as the only identified inducible IEG product that is locally translated at
activated synapses.
Recent studies have provided additional information about Arc that makes
it an intriguing candidate for memory-related studies. Guzowski et al. injected Arc
antisense oligonucleotides into the brains of rats and using a spatial water maze
task demonstrated that long-term memory consolidation was significantly
impaired, while short-term cognition was not (Guzowski et al., 2000). Also, in
concordance with the idea that early phase LTP corresponds to short-term
memory, and late phase LTP (which requires new protein synthesis) with longterm memory, animals injected with Arc antisense oligos were able to undergo
induction of LTP, but were unable to maintain it. Arc induction also seems
dependent upon NMDAR activation, while AMPAR stimulation alone will not
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produce a rise in expression (Steward and Worley, 2001). Additionally, animals
exposed to an enriched environment have increased hippocampal levels of Arc
expression, and animals most proficient at spatial tasks have had correlated
elevations in Arc mRNA levels (Montag-Sallaz et al., 1999;Pinaud et al.,
2001;Guzowski et al., 2001). The expression of Arc appears to be highest
following a novel task, as demonstrated by a decrease in expression in mice
over-trained for the same trial. Likewise, by simply changing the location of the
platform in the water maze, Arc levels become elevated (Kelly and Deadwyler,
2002). All of these data correlate well with the notion that some sort of enduring
synaptic rearrangement is essential for the consolidation of long-term memory.
Taken together with the properties of the Arc protein and its expression patterns,
these findings belie the possible mechanistic role of Arc in memory formation.
Arc co-sediments with F-actin macroaggregates and bears some
homology with α-spectrin, further implicating it in mediation of synaptic plasticity.
The protein is a 45kD hydrophilic protein with several phosphorylation sites
including sites for PKC and CaMKII. Arc is expressed basally at low levels, with
the thought being that this protein is induced during any NMDA-mediated
synaptic activity. This relationship was established by findings of a reduction in
the basal mRNA levels following NMDAR antagonist, MK-801, administration
(Lyford et al., 1995), accompanied by a robust increase when animals receive
methamphetamine (Kodama et al., 1998). The expression of Arc mRNA is almost
exclusive to the brain, and predominates in the hippocampus and cortex. Cortical
levels are actually higher than those of the hippocampus, further implicating a
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functional relationship with long-term memory storage through LTP maintenance
and lasting synaptic changes in the PSDs of cortical neurons. Following an LTP
inducing stimulus, the rapid induction of mRNA reaches a maximal level within 1
hour and this peak is maintained for 8 hours, followed by a return to basal
expression levels within 24 hours.
A signal within the mRNA itself seems the mechanism for the selective
transport of particular mRNAs to the dendrites. This trafficking is a two-step
process consisting of two types of signals within the molecule; a routing signal,
for selective nuclear retention or molecular layer transport, and a localization
signal, that results in the selective accumulation of mRNA at a particular
intracellular site (Steward et al., 1998). Both Ca2+ and cAMP induce Arc
transcription, and this inducibility is dependent upon the activation of PKA and
the ERK/MAPK cascade (Waltereit et al., 2001). Interestingly, the Arc promoter
lacks a complete putative CRE site, tentatively eliminating CREB transcriptional
activation, a common downstream target of the MAPK pathway. The promoter
does however contain an AP-1 binding site, a transcription factor composed of
the two IEGs, c-fos and c-jun, possibly indicating a potential regulatory
mechanism that provides activity-dependent modulation of transcriptional
activation.
Growth factors have also been implicated in LTP-promoted Arc induction,
namely insulin (Kremerskothen et al., 2002) and brain-derived neurotrophin
factor (BDNF;Yin et al., 2002). Insulin seems to mediate Arc expression through
the ERK/MAPK cascade, and BDNF, known to activate CREB and the MAPK
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cascade, has also been linked to an increased expression of Arc. Therefore,
Ca++ influx that activates PKA and subsequently the MAPK cascade, may
mediate the CREB-independent activation of Arc transcription, emphasizing the
possibly significant roles that effector IEGs and the ERK/MAPK cascade play in
cognitive retention.

THE ROLE OF NA+/K+ ATPASE IN COGNITIVE FUNCTION.
The role of the membrane-bound Na+/K+ ATPase is to transport Na+ ions
out of the cytosol and K+ ions in to the cell against their concentration gradient
thereby establishing a membrane potential to allow subsequent depolarizations.
This process requires energy input that is derived from ATP hydrolysis. The
importance of this enzyme in cognitive processes is belied by its consumption of
~40% of total cerebral ATP. It has been previously established that specific
inhibition of Na+/K+ ATPase by oubain, prevents the consolidation of memory
(Mark and Watts, 1971;Watts and Mark, 1971), and therefore it is postulated that
the ability of neurons to conduct action potentials or facilitate LTP is critically
dependent on the integrity and functionality of this enzyme.
In addition to 3 tissue-specific subtypes of the Na+/K+ ATPase, there are two
major subunits that comprise each molecule; a catalytic α subunit and a
membrane anchoring β subunit. Very recent evidence indicates the presence of a
cerebral γ subunit, a member of the FXYD family, which positively regulates the
activity of Na+/K+ ATPase (Crambert et al., 2003). This subunit is a single
transmembrane protein, however much of its function has yet to be determined.
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The activity of Na+/K+ ATPase can be increased or decreased by pharmacologic
intervention with the anti-convulsant phenytoin or the cardiac glycoside digitalis,
respectively. Phenytoin decreases the intracellular concentration of Na+ ions by
two possible mechanisms; inhibition of voltage gated Na+ channels by locking
them in an inactivated state (Worley and Baraban, 1987;Kuo and Bean, 1994)
and/or the hyper-activation of Na+/K+ ATPase (Gutman and Boonyaviroj, 1977)
by preventing the phosphorylation of the α subunit and thereby blocking its
internalization (Guillaume et al., 1989).
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ABSTRACT
A critical question in Alzheimer's disease (AD) research is the cause of memory
loss that leads to dementia. The APP+PS1 transgenic mouse is a model for
amyloid deposition, and like AD, the mice develop memory deficits as amyloid
deposits accumulate. We profiled gene expression in these transgenic mice by
microarray and quantitative RT-PCR (qRT-PCR). At the age when these animals
developed cognitive dysfunction, they had reduced mRNA expression of several
genes essential for LTP and memory formation (Arc, Zif268, NR2B, GluR1,
Homer-1a, Nur77/TR3). These changes appeared to be related to amyloid
deposition, as mRNA expression was unchanged in the regions that did not
accumulate amyloid. Transgene expression was similar in both amyloidcontaining and amyloid-free regions of the brain. Interestingly, these changes
occurred without apparent changes in synaptic structure, as a number of
presynaptic marker proteins (GAP-43, synapsin, synaptophysin, synaptopodin,
synaptotagmin, syntaxin), remained stable. Additionally, a number of genes
related to inflammation were elevated in transgenic mice, primarily in the regions
containing amyloid. In AD cortical tissue the same memory-associated genes
were down-regulated. However, all synaptic and neuronal transcripts were
reduced, implying that the loss of neurons and synapses contributed to these
changes. We conclude that reduced expression of selected genes associated
with memory consolidation are linked to memory loss in both circumstances. This
suggests that the memory loss in APP+PS1 transgenic mice may model the early
memory dysfunction in AD prior to the degeneration of synapses and neurons.
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INTRODUCTION
Memory loss is an early and progressive symptom of Alzheimer’s disease (AD).
During the period of cognitive decline, pathological hallmarks such as amyloid
plaques and neurofibrillary tangles become evident (Selkoe and Hardy, 2002). In
the later stages of AD, there is a profound loss of synaptic markers, but early in
the disease this loss is modest, and in some instances not discernable
(Mukaetova-Ladinska et al., 2000;Tiraboschi et al., 2000;Masliah et al.,
2001;Minger et al., 2001). A clue to understanding the basis of early memory
loss in AD may come from transgenic mice that develop impaired memory
function associated with amyloid deposition, but never show the extensive loss of
synapses or neurons typical of AD.
The APP+PS1 mouse model of amyloid deposition develops a memory
loss that is consistently observed by 15 months of age (Morgan et al.,
2000;Arendash et al., 2001) and is correlated with the extent of amyloid
deposition. Like AD, these mice deposit amyloid primarily in the cerebral cortex
and hippocampus, leaving the brainstem and cerebellum largely unaffected
(Holcomb et al., 1998;Holcomb et al., 1999;Gordon et al., 2002). To assess
changes that occur in the brain in conjunction with amyloid- associated memory
loss we used microarray analysis and qRT-PCR to survey the genes that were
up- or down-regulated in amyloid-containing regions of APP+PS-1 transgenic
mouse brain. We found that the amyloid-containing regions of the transgenic
mouse brain had high levels of expression of inflammation-associated genes, a
characteristic that is also typical of AD brain. However, the most intriguing part of
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the gene expression profile was a selective decrease in transgenic mice of genes
known to be important in long-term potentiation (LTP) and memory consolidation,
restricted to amyloid-containing brain regions. Expression of genes involved in
synaptic and neuronal structure was severely diminished in the human AD brain,
but the transgenic animals did not show decreases in any of these genes. This
suggests that the memory deficits in the early stages of human AD may be the
result of dysfunctional changes that precede the frank loss of synapses.

METHODS
Materials
Mice were bred in our facility and genotyped using previously described
methods (Gordon et al., 2001). All mice were 17-18 months of age at time of
death. Mice were deeply anesthetized with pentobarbital (100 mg/kg) and
perfused transcardially with phosphate buffered saline. Brains were quickly
removed and amyloid-containing (cortex and hippocampus) and amyloid-free
areas (cerebellum, striatum, and brainstem) were immediately dissected and
frozen on dry ice. For microarray analysis, cortex and hippocampus were pooled
and dealt with as amyloid bearing samples, while cerebellum, striatum and
brainstem were combined and treated as amyloid-free tissues. For qRT-PCR,
hippocampal RNA alone was isolated and regarded as amyloid-containing while
cerebellum alone was used for amyloid-free analysis. Transgenic and nontransgenic animals were sacrificed in random order to minimize unintentional
bias in handling of the samples. The working memory performance of the
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APP+PS1 mice used in these studies was significantly different from their nontransgenic littermates used as controls (Austin et al., 2003).
Fresh-frozen human cerebellar and medial temporal gyrus (MTG)
specimens were obtained from the Brain Donation Program at Sun Health
Research Institute in Sun City, Arizona. Subjects with a clinical history of
dementia were diagnosed as AD using neuropathologic consensus criteria,
including those published by CERAD (Mirra et al., 1991) and the NIA-Reagan
Institute (1997). Control subjects did not have a clinical history of dementia and
did not meet neuropathologic criteria for AD or other neurologic disorders. The
average postmortem intervals were 2.6 h for AD and 2.3 h for control specimens
(6 Female, 2 Male for AD; 6 Female, 2 Male for age matched control). The
average age for the AD specimens was 87 years, and the average age for the
controls was 88 years.

Microarray analysis
Brain specimens from four 17-18 mo old APP+PS1 transgenic mice or four
non-transgenic littermates were grouped into two categories; amyloid-containing
(cortex and hippocampus) and amyloid-free areas (cerebellum, striatum, and
brainstem). Messenger RNA was isolated from individual tissue samples,
labeled with Cy3 or Cy5, and used for competitive hybridization to cDNA
microarrays as described (Loring et al., 2001). Samples were analyzed pair wise
(matched areas from transgenic and non-transgenic animals) on a total of 16
microarrays. The microarrays (8 Rat LifeArray 1 and 8 Rat LifeArray 2; 4 each
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for the amyloid-containing region samples and the amyloid-free regions) used for
this study were constructed from a collection of 15,981 rodent cDNAs
representing 10,060 different genes (Incyte Genomics, Inc). All of the sequences
differentially expressed in the present study are more than 90% identical in
mouse and rat and competitive hybridization of rat and mouse brain transcripts to
these microarrays showed that 89% of the cDNA clones hybridized mouse and
rat samples equally (data not shown). Microarrays constructed from the same
library are currently available commercially from Agilent Technologies (Palo Alto,
CA). Data collected from the microarray hybridizations were subjected to two
low-frequency data correction algorithms to compensate for systematic variations
in data quality as described previously (Yue et al., 2001).
To minimize the detection of false positive signals (Type I statistical
errors), the data were subjected to a two-stage criterion to identify genes of
interest. The limit of detection of differential expression (LDDE) was calculated to
be ±1.4 fold by multiple quality control hybridizations as previously described
(Yue et al., 2001). This LDDE indicates that in a single hybridization of an RNA
sample against itself a 1.4 fold difference occurred with a P < 0.01. To further
limit the number of false positive genes identified, we required that in 3 of the 4
individual hybridizations the differential expression value had to exceed 1.4 for a
given gene to be analyzed further. For the second criterion, the statistical
significance of the average differential expression value for any gene was
calculated using Z-scores and a NORMSDIST function, and was required to
exceed a value of 1.4 (not simply 1.0) with a P < 0.05. In cases where a given
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gene was represented by multiple sequences on the microarray, all data were
combined for statistical analysis. Detailed analysis indicates that some
sequences on microarrays are more variable in self-self hybridizations than
others, leading to multiple false positives if one simply uses a differential
expression value cutoff without sufficient replicates for statistical determinations.
Moreover, because the variance estimates are sequence-specific, the use of Zscores based upon the variance estimate of all spots on the array is not always
appropriate, and should not be used as the only criterion in determining
differentially expressed genes. One caveat of using these stringent criteria is an
increased probability of Type II statistical errors (false negatives). Still we believe
this approach will identify those sequences which are most robustly and
consistently modified.
For samples exhibiting significant differential expression in the amyloidcontaining and amyloid-free brain areas of transgenic animals, a one-way
analysis of variance was performed A planned post-hoc comparison of means
(least significant difference) was used to determine if the expression was
significantly different in the amyloid-containing vs. the amyloid-free brain areas
for individual genes. Each of the microarray clones that showed differential
hybridization was unambiguously annotated by comparing its sequence (200-700
bp) to GenBank using the BLAST 2 algorithm.
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qRT-PCR
Total RNA was prepared from dissected cerebellar and hippocampal
tissue of 8 APP+PS1 mice and 8 non-transgenic littermates that were 18-19
months old. Memory deficits and amyloid burden were established in the
transgenic mice by radial arm water maze testing and immunohistochemical
methods, respectively (Austin et al., 2003). Human temporal cortex (medial
temporal gyrus; Brodmans area 21) and cerebellar tissue samples from 8 AD
patients and 8 age-matched controls were pulverized by mortar and pestle on dry
ice and 10-30mg of this powdered tissue was used to extract RNA. The
homogenate from rotor-stator emulsification (Tissuemizer) of all tissues used
were applied to RNeasy mini-spin columns (Qiagen) with on-column DNase
treatment followed by elution with RNase-free water, according to the
manufacturer’s specifications. All total RNA samples were then reverse
transcribed with a 1:1 mixture of oligo dT (25ng/µl, Invitrogen) and random
hexamers (2.5ng/µl, Invitrogen) to provide ample cDNA synthesis from both 18S
rRNA (Schmittgen and Zakrajsek, 2000) and poly-adenylated mRNA. The final
reverse transcription reaction included template (described below), 1M betaine
(Sigma-Aldrich), providing more heat lability to nucleic acid and protein thermostabilization, 1x cDNA first-strand synthesis buffer (Invitrogen), 7mM MgCl, 1mM
dNTPs (Each A,G,C,T, Invitrogen), 40 units of RNaseOut (Invitrogen), 3mM DTT
(Invitrogen), and 25 units of recombinant Superscript II reverse transcriptase (RT,
Invitrogen). The reaction was brought to 20µl with water and then incubated for
15 minutes at 25°C, followed by 30 minutes at 42°C and then 30 minutes at
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60°C. The reaction was then heated at 95°C to denature the enzymes and stop
the reaction. A standard curve was established within the reverse transcription
reaction by adding total RNA (template) from an intra-experimental mouse or
human RNA pool covering 3 logs (50, 20, 10, 5, 2, 1, 0.5 & 0.2ng) to separate
wells. Two mass quantities (10 & 2ng) of total RNA from all samples being
investigated were added to individual wells within the reverse transcription
reaction for comparison to the standard curve. The RNA standard curve verifies
the linearity of the RT-PCR reaction and controls for slight inefficiencies in the
transcription and amplification steps of the procedure (below).
Primer pairs for qRT-PCR were generated to amplify ~100bp fragments of
the gene of interest using the web-based applications Primer3 and the Oligo
Toolkit at http://www.operon.com/. These oligos were tailored according to the
species being analyzed. Primers were initially optimized using a PCR reaction
followed by agarose gel analysis. If ethidium bromide staining revealed a single
band, the primer concentrations were optimized by comparing at least three
concentrations of each primer and noting which combination was most efficient at
generating a PCR product (using SYBR green detection, see below), without
producing signal in control wells lacking template. Experimental wells containing
cDNA 25µl PCR reactions were run in triplicate consisting of a master mix
containing 12.5µl of 2x SYBR Green Master Mix (Applied Biosystems), 0.25-4.5µl
of forward and reverse primers in varied combinations, either 2µl of cDNA from
an RT reaction or 2µl of water, to control for non-specific amplification due to selfpriming or contamination. The remainder of the 25µl volume was achieved by
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adding water. 96-well plates were mixed by pipetting and then centrifuged. Twostep PCR was run on the MJ Research Opticon (Boston, MA) as follows; 1 cycle
of 95˚C for 15 minutes followed by 40 cycles of 95˚C for 15 seconds and 60-65˚C
for 1 minute (primer annealing temperature is decided according to the Operon
website calculations). This was followed by melt curve analysis beginning at 55˚C
and increasing by 1˚C to 100˚C every 10 seconds, with fluorescence measured
at every interval. None of the primer pairs demonstrated more than 1 peak of
fluorescence as derived from the Opticon software, indicating a single gene
product without primer-dimer formation.
The target gene primers demonstrated similar amplification efficiencies as
compared with 18S ribosomal RNA, allowing for quantitation of fold-change using
18S signals to normalize the results for the quantity of starting RNA. The slope of
the regression line for the standard curve determined efficiency, which varied by
less than 5% for all amplicons. Samples were run in triplicate, with both the 10ng
and 2ng RT reactions represented for each. Standard curve samples were
included on all plates to avoid errors due to minor plate-to-plate variations in
amplification efficiency. The standard curve was calculated by plotting the
threshold cycle (Ct, the point at which relative fluorescence exceeds a fixed value
above background against the log nanogram quantity of RNA added to the RT
reactions). A linear regression was performed and the slope-relating Ct to log
RNA was calculated. The average Ct for each sample was then used to
determine the corresponding log ng of standard RNA using the slope of the
standard curve. These logarithmic values were then converted to a mass
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quantity of standard RNA according to Ct. These mass values for the genes of
interest were then divided by the 18S values of the same sample to determine
fold-change in expression relative to the standard RNA pool. For each region
these fold change values for samples in the experimental (transgenic or AD) and
control (non-transgenic or age-matched non-diseased) groups were analyzed for
significance using 1-way ANOVAs. The differential expression value between
regions was similarly compared using one-way ANOVA.

RESULTS
The mice used for analysis were 17-18 month- old APP+PS1 transgenic
mice that demonstrated impaired working memory performance compared to
non-transgenic littermates (Morgan et al., 2000;Austin et al., 2003). Different
mice were used for microarray and qRT-PCR studies. We first used a
competitive hybridization approach to compare transcripts from transgenic
mouse brain with matched non-transgenic tissues on cDNA microarrays. Instead
of assigning an arbitrary cut-off value to detect changes in regulation, the
microarray analysis was based on multiple arrays with independent samples and
statistical comparisons to determine those genes that were differentially
expressed (see Methods). Using the rigorous criteria for the microarray analysis
set forth above (see Methods), only five genes demonstrated significantly
decreased expression in the amyloid-containing areas (hippocampus plus cortex
for the array studies) of the transgenic animals (Table 1). This group of genes
included three genes that are essential for normal memory function (Arc, Zif268,
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Nur77/TR3) and two associated with neuronal/synaptic activity (Na+, K+ ATPase
α III, calsyntenin). Except for Zif268 (see below) these reductions were restricted
to amyloid-containing brain regions, and did not occur in regions from the same
mice that were amyloid-free (cerebellum, striatum, brainstem in the array studies;
Table 1), even though transgene expression was high in these regions (see
below).
Using qRT-PCR, we saw a similar pattern of specific amyloid-associated
down-regulation for most of the genes in this group (Table 1). Because of the
50% reduction in the memory-associated genes Zif268 and Arc found with the
microarray, we expanded the qRT-PCR analysis to include other genes related to
synaptic function and memory processes (Figure 1). This analysis showed that
the transcript for the ionotropic glutamate receptor 1 (GluR1/AMPA1) was downregulated by 30% and the NMDA receptor subunit 2B (NR2B) RNA, known to be
critical for cognitive processes (Tang et al., 1999), was decreased by 18% in
amyloid-containing tissue (hippocampus alone for qRT-PCR studies). Expression
of Homer-1a, which is a member of the Homer family of metabotropic glutamate
receptor binding proteins (Brakeman et al., 1997) was reduced by 40%. Not only
were these genes significantly down regulated in comparison to non-transgenic
mice, they were also decreased significantly compared to the expression in
amyloid-free tissue (cerebellum only for qRT-PCR studies) for the same animals
(bracket above bars in Figure 1). Only one of the synaptic plasticity-related genes
was significantly down-regulated in the amyloid-free region; Zif268 expression
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measured by qRT-PCR was 18% lower in the cerebellum, which was still
significantly less reduced than in the hippocampus (Figure 1).
Not all of the synaptic plasticity genes we examined were changed in the
transgenic mice. Expression of synaptopodin (Mundel et al., 1997), which is
argued to be involved in synaptic plasticity, was not changed, nor was GAP-43,
also involved in synaptic plasticity and sprouting (Routtenberg et al., 2000),
suggesting that not all synaptic-plasticity genes were modified in the transgenic
animals. Other synaptic/neuronal markers were also expressed at normal levels
in the transgenic animals, including synaptophysin, neurofilament-M, synapsin-1
and synaptotagmin V. The stability of these largely presynaptic markers was
also observed in the results from the microarray study (Table 1).
The microarray analyses revealed an up-regulation of a group of genes
associated with inflammation and the acute phase response (Table 2). We
quantified the up-regulation of three of these genes by qRT-PCR (GFAP, ApoE,
and vimentin). Expression of glial fibrillary acidic protein (GFAP), an astrocytespecific intermediate filament, was increased by 6.3 fold in the APP+PS1 mice
compared with non-transgenic littermates (Table 3). This reflects the astrocyte
proliferation known to occur in the APP+PS1 animals (Holcomb et al., 1998) and
is consistent with earlier immunoassay results measuring this protein (Gordon et
al., 2002). Additionally, another non-neuronal intermediate filament, vimentin,
was up-regulated by more than two-fold and Apolipoprotein E (ApoE), another
acute phase protein, was up-regulated to a lesser extent. These data are
consistent with earlier reports describing reproducible glial activation and acute
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phase reactivity in the APP+PS1 mice (Holcomb et al., 1998;Matsuoka et al.,
2001; Gordon et al., 2002). Most of these genes were unaffected in the areas of
the transgenic brain that were relatively free of plaques. However, a few of the
genes were also upregulated in non-plaque-bearing regions (Table 3). Two of
these genes were highly expressed because they contained sequence that was
homologous to the sequence of the APP transgene. The APP transcripts on the
microarray and the array sequences corresponding to the prion protein 5’
untranslated region (part of the transgene promoter construct (Hsiao et al., 1996)
were elevated to the same extent in both the amyloid-containing and amyloidfree regions. Sequences on the microarray that encoded other regions of the
prion gene were unaffected in transgenic animals (not shown). Notably, except
for the transgenes and two others, the elevation in the amyloid containing regions
was significantly greater than in the amyloid-free regions of the transgenic brain
(Table 3, asterisks). Coupled with the absence of up-regulation in amyloid-free
regions for most of the genes in Table 2, it seems likely that the modest upregulation of several inflammation related genes in these amyloid-free regions
reflects a lower level of generalized inflammation in these areas.
We considered it critical to compare the expression of the synaptic marker
genes in the mouse model with specimens from AD patients. A previous
microarray analysis (Loring et al., 2001) indicated that many markers of
synapses were decreased in the amyloid-containing areas of AD brain. We
extended this analysis by qRT-PCR measurements of a group of synaptic
markers in the medial temporal gyrus of the cerebral cortex (MTG; Brodman's
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area 21) and cerebellum of 8 AD patients and 8 cognitively normal age-matched
controls. As shown in Figure 2, all of the postsynaptic plasticity associated
transcripts we analyzed were significantly under-expressed by more than 50% in
the amyloid-containing cortical region, while the amyloid-free cerebellar tissue
lacked any significant change in expression of the same genes, consistent with
the relative sparing of the cerebellum in AD. In this manner the pattern of
changes in transgenic mice and AD cases was similar. However, in contrast to
the observations we made for the mouse, in samples of AD MTG all of the other
synaptic markers (synaptophysin, synapsin, synaptopodin, synaptotagmin, GAP43) were also reduced, as was neurofilament M. Similar to the transgenic
mouse, GFAP was elevated in the amyloid-containing region of the AD brain.
Also similar to the mouse, there were no significant changes in the amyloid-free
human cerebellum, coupling amyloid to the apparent loss of mRNA in the AD
samples. These data are consistent with the considerable evidence showing
neurodegeneration and synaptic loss in amyloid-containing regions of late stage
AD. The results also highlight the similarities and differences between the severe
loss of most cognitive function in AD and the relatively selective memory loss in
amyloid-depositing transgenic mice which do not undergo neurodegeneration
(Matsuoka et al., 2001).

DISCUSSION
The results of our microarray and qRT-PCR study show that the expression of
several postsynaptic genes known to be integral for the establishment of LTP
39

and long-term memory, was selectively down-regulated in the amyloidcontaining regions of memory-deficient APP+PS1 mice. The amyloid-free
regions of these transgenic mice do not exhibit the same down-regulation.
Additionally, several presynaptic genes that are often used as synaptic or
neuronal markers are unaltered in these animals, similar to recent microarray
findings in APP transgenic mice at an age preceding amyloid deposition (Stein
and Johnson, 2002). These findings indicate that the failure of APP+PS1 mice to
consolidate information for future recall may be precipitated by the amyloid
dependent down-regulation of genes known to be critical for cognitive function.
Late phase LTP is thought to correspond to some forms of long-term
memory consolidation because of the requirement for de novo protein synthesis
for both processes (Morris, 1998). In APP transgenic mice, the formation of LTP
is impaired in some, but not all studies (Chapman et al., 1999;Larson et al.,
1999;Fitzjohn et al., 2001). Recently it was found that oligomeric forms of the Aß
peptide were particularly effective at impairing LTP when injected into the
hippocampus in vivo (Walsh et al., 2002). Of particular relevance are previous
observations that the plasticity-related genes we examined are essential for late
phase LTP and long-term memory formation (Bolshakov et al., 1997;Ma et al.,
1999). Antisense oligonucleotides against Arc mRNA intracranially injected into
rats eliminated both late phase LTP and long-term memory formation without
affecting short-term forms of both processes(Guzowski et al., 2000). Mice with a
targeted inactivation of Zif268 also lack the ability to express long-term synaptic
and behavioral plasticity, although short-term forms of plasticity remain intact
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(Jones et al., 2001). It has been reported that over-expression of the NR2B
subunit leads to improved memory function (Tang et al., 1999), while intracranial
injection of antisense oligonucleotides directed against NR2B mRNA inhibits LTP
and cognitive function (Clayton et al., 2002). Additionally, there is a large amount
of evidence suggesting an aggregation of AMPA receptors (GluRs) and
metabotropic glutamate receptors (mGluRs) with NMDA receptors via proteins
such as Homer and PSD95, further linking LTP with memory storage (Ango et
al., 2000;Xiao et al., 1998). Homer-1a is elevated after synaptic activation and
plays a role in targeting mGluRs to synapses (Ango et al., 2000). Therefore all of
these genes are known to play a role in cognitive ability, and their selective
down-regulation in a mouse model of amyloid-associated memory deficits
establishes them as possible candidates for pharmacotherapeutic approaches to
AD.
Although many of the genes known to influence memory were diminished
in the APP+PS1 mice, there were several in our study that did not show downregulated expression. GAP-43, one of the unchanged genes, has been shown to
improve cognitive function when over-expressed in transgenic mice (Routtenberg
et al., 2000). Synaptopodin, another protein linked to plasticity (Mundel et al.,
1997;Deller et al., 2000;Yamazaki et al., 2001), is also stable in the amyloidcontaining regions of the APP+PS1 mouse brain. These data imply that amyloid
is selective in down-regulating only certain memory-associated genes, which are
mostly postsynaptic. There are several mechanisms which might account for
these changes. One possibility is direct interaction of Aβ with one or more signal
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transduction pathways. Alternatively, the regulation could be via an indirect
pathway involving the acute phase response (e.g. cytokine effects secondary to
amyloid-induced microglia activation). The first idea is supported by the fact that
several of the down-regulated genes are immediate early genes that can be
induced by activating the ERK signaling cascade (Davis et al., 2000;Mazzucchelli
et al., 2002). Aβ itself appears capable of modifying ERK signaling (Dineley et al.,
2001) potentially interfering with expression of these genes. Alternatively, as the
induction of these IEGs is dependent upon synaptic activity, a generalized
decrease in neuronal activity caused by Aβ might also explain the reductions in
expression. There is also evidence supporting the indirect mode of regulation,
since the glial reactions leading to the activation of inflammatory mediators
correspond temporally to the period when memory loss is occurring (Gordon et
al., 2002). Dissociating between these mechanisms and identifying the specific
components involved will also benefit development of rational pharmacotherapies
for AD.
We observed that many of the memory-associated genes were similarly
deficient in the amyloid-containing regions of the human AD brain, confirming
earlier reports from our group and others (Ginsberg et al., 2000;Loring et al.,
2001;Bi and Sze, 2002). However, interpretation of this observation is
complicated by the fact that multiple neuronal and synaptic marker genes were
also under-expressed in the AD cortex we examined. But our samples were from
relatively late-stage AD, when amyloid deposition and neuronal dysfunction are
extensive, and several reports indicate that widespread loss of synapses appears
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to follow, not precede, loss of memory function. In a detailed study of synaptic
markers during the course of AD, it was reported that loss of synaptic markers
only occurred in Braak stages 5 & 6, late in the disease when the pathology is
most widespread (Mukaetova-Ladinska et al., 2000). Another study (Tiraboschi
et al., 2000) failed to detect changes in the synaptic markers synaptophysin or
choline acetyl transferase in mild AD (MMSE = 20) and a third report found that
mildly demented individuals (CDR 0.5-1) had no change in synaptotagmin or
GAP43, although a slight reduction in synaptophysin was found which worsened
as the disease progressed (Masliah et al., 2001). A study by Minger et al found
that only in AD cases that were severe (MMSE < 4) was there a significant
reduction in choline acetyltransferase, synaptophysin, syntaxin or SNAP-25.
None of these studies examined the synaptic plasticity markers that we observed
to be decreased in the transgenic mice. In light of this evidence and our
observations, we propose that the APP+PS1 mouse that 1) develops both
forebrain-specific amyloid deposits and memory deficits, 2) suffers acute phase
reactions in the brain, and 3) has decreased memory-associated gene
expression without the loss of synaptic integrity markers, is likely to be an
appropriate model for anterograde amnesias found in early stage AD.
Transgenic models for human disease have become a critical tool in the
progression of therapeutic strategies to clinical trials. It is crucial, therefore, to
validate the models for specific characteristics of the human disease. This report
describes further characterization of a transgenic mouse model that constitutively
expresses both the human APP and PS1 genes containing mutations that are
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known to accelerate amyloid deposition and dementia in AD cases. The
transcripts of several postsynaptic genes that are thought to be essential for the
retention of memory and maintenance of LTP are specifically down-regulated in
the cognitive areas of APP+PS1 mouse brain without the loss of expression of
genes involved in synaptic function. When these genes were analyzed in late
stage human AD temporal cortex, we found that the same memory-associated
genes were down-regulated, but unlike the mouse, all markers for synaptic
integrity and neuronal stability were also under-expressed. Along with the
activation of glial cells and induction of acute phase reactants, the fact that the
APP+PS1 mice deposit amyloid in the forebrain, develop anterograde amnesia
and have altered expression of these memory-associated genes specifically in
the cognitive domains of the brain suggests that some form of amyloid is
facilitating the memory loss in these animals.
These data also contribute to the growing pool of evidence that specific
genes such as Arc, Zif268, NR2B, and Homer-1a are critical to normal memory
function, and that their dysregulation may underlie the early phase of memory
loss that occurs in AD. Therefore it will be of great interest to evaluate methods
to up-regulate these genes as potential therapeutic targets for use in early-stage
AD and possibly other disorders involving memory deficiency.
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TABLE 1. Expression of neuronal genes in transgenic mice compared to nontransgenic mice
(array and qRT-PCR data).
qRT-PCR Data

Array Data
Marker
mRNA

Protein Function

Percentage of nontransgenic mean
± SEM. (z-score in parentheses)

Percentage of
nontransgenic mean ±
SEM

AmyloidContaining Area

Amyloid-Free
Area

AmyloidContaining
Area

AmyloidFree
Area

Arc

LTP-associated structural

64 ± 3* (2.8)

108 ± 6 (0.4)

48 ± 10*

97 ± 5

Calsyntenin

Postsynaptic Ca(2+) signaling

64 ± 3* (2.8)

79 ± 5 (1.33)

99 ± 9

nd

Gap43

Neuritic growth, plasticity

115 ± 7 (0.75)

87 ± 7 (0.75)

104 ± 10

94 ± 4

GAPDH

Energy metabolism

91 ± 4 (0.49)

97 ± 1 (0.15)

82 ± 7

nd

GluR1

Postsynaptic receptor

102 ± 2 (0.1)

105 ± 3 (0.25)

70 ± 10*

95 ± 6

Homer-1a

LTP-associated, regulatory

nd

nd

60 ± 7*

95 ± 9

Na, K ATPase αIII

Neuronal ion gradient,
transmission

66 ± 4* (2.6)

77 ± 3 (1.5)

57 ± 4*

99 ± 5

NAB2

LTP-related, regulatory

nd

nd

115 ± 7

nd

Neurofilament M

Neuronal structural

103 ± 1 (0.15)

104 ± 1 (0.20)

82 ± 7

nd

“*” significantly different from nontransgenic mice at P<0.05
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TABLE 1 (CONTINUED)

qRT-PCR Data

Array Data
Marker
mRNA

Protein Function

Percentage of nontransgenic mean
± SEM. (z-score in parentheses)

Percentage of
nontransgenic mean ±
SEM

AmyloidContaining Area

Amyloid-Free
Area

AmyloidContaining
Area

AmyloidFree
Area

nd

nd

82 ± 5*

99 ± 5

NR2B

Receptor implicated in memory
consolidation

Nur-77

LTP-associated, regulatory

61 ± 4* (3.2)

77 ± 1 (1.5)

nd

nd

Synapsin

Presynaptic vesicle-associated

71 ± 8* (2.0)

92 ± 2 (0.4)

103 ± 7

82 ± 18

Synaptophysin

Presynaptic vesicle-associated

126 ± 8 (1.3)

91 ± 4 (0.5)

101 ± 5

98 ± 5

Synaptopodin

LTP-associated structural

nd

nd

91 ± 5

nd

Synaptotagmin 5

Presynaptic vesicle-associated

98 ± 4 (0.1)

106 ± 2 (0.3)

106 ± 19

nd

Syntaxin

Presynaptic vesicle-associated

nd

nd

94 ± 7

nd

Zif268

LTP-associated, regulatory

60 ± 5* (3.3)

88 ± 8 (0.68)

45 ± 8*

82 ± 3*

“*” significantly different from nontransgenic mice at P<0.05
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TABLE 2. Genes that are up-regulated in amyloid-containing areas of transgenic
mice brains compared to the same areas of nontransgenic mice brains
(microarray data).
Function and Location

Gene Name
Alpha-1 type III collagen

Secreted/
Cell Surface
Inflammation

Cytoskeletal

Lysosomal

Percentage of
nontransgenic mean ± SEM
(z-score in parentheses)
162 ± 7* (3.3)

Alpha-fibrinogen Fga

368 ± 46* (13.6)

Beta-2-microglobulin

203 ± 9* (5.4)

Beta-5 integrin

190 ± 11* (4.7)

Beta-galactoside-binding lectin

177 ± 14* (4.1)

Cd63

193 ± 16* (4.9)

Complement component C1q alpha chain

289 ± 27* (9.6)

Complement component C1q beta chain

200 ± 16* (5.2)

Complement component C4

297 ± 22* (10.1)

Histidine-rich glycoprotein

172 ± 13* (3.8)

Ig heavy chain VDJh2 region

160 ± 10* (3.2)

Lysozyme

183 ± 8* (4.4)

MHC class I

166 ± 6* (3.5)

MHC class I A1(f) alpha chain RT1.A1(f)

182 ± 8* (4.3)

Transferrin

178 ± 10* (4.1)

Tyrosine kinase binding protein

254 ± 6* (7.9)

Glial fibrillary acidic protein

483 ± 64* (19.4)

Vimentin

181 ± 14* (4.3)

Cathepsin D

253 ± 32* (7.9)

Cathepsin S

248 ± 21* (7.6)

Cathepsin Y

187 ± 22* (4.6)

“*” All entries are significantly different from amyloid-containing regions of nontransgenic mice at P < 0.05
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TABLE 2 (CONTINUED).

Function and Location

Gene Name
Acyl-CoA binding protein

Lipid
binding

Acute-phase
reaction

Intracellular

Secreted/
Cell
Surface

Percentage of
nontransgenic mean ± SEM
(z-score in parentheses)
166 ± 6* (3.5)

Apolipoprotein D

159 ± 10* (3.2)

Apolipoprotein E

160 ± 4* (3.2)

Niemann Pick type C2

180 ± 12* (4.2)

Alpha-D-mannosidase

162 ± 7* (3.3)

Cystathionine beta-synthase

377 ± 22* (14.1)

Kelch-like 1

189 ± 15* (4.7)

Mitochondrial Epsilon-trimethyllysine 2oxoglutarate dioxygenase
Serine protease inhibitor
SPI-2 serine protease inhibitor

175 ± 21* (4.0)
161 ± 21* (3.3)
176 ± 14* (4.0)

Thyroid hormone receptor alpha

618 ± 73* (26.1)

“*” All entries are significantly different from amyloid-containing regions of nontransgenic mice at P < 0.05
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TABLE 3. Genes that are up-regulated in both amyloid-containing brain regions and amyloid-free
brain regions of transgenic mice (array and qRT-PCR data).

Array Data
Marker RNA

Percentage of nontransgenic mean
± SEM
AmyloidContaining Area

Transgene

Inflammation

Amyloid-Free
Area

qRT-PCR Data
Percentage of
nontransgenic mean ±
SEM
AmyloidContaining
Area

AmyloidFree Area

APP

192 ± 7 (4.8)

209 ± 7 (5.7)

nd

nd

Prion protein (UTR)

223 ± 15 (6.4)

242 ± 14 (7.3)

nd

nd

Apolipoprotein E

160 ± 4 (3.2)

171 ± 10 (3.8)

156 ± 16

nd

Alpha-1 type III collagen

162 ± 7 (3.3)

167 ± 12 (3.6)

nd

nd

Complement component C1q
alpha chain

289 ± 27* (9.7)

182 ± 18* (4.3)

nd

nd

Complement component C4

297 ± 22* (10.1)

154 ± 8* (2.9)

nd

nd

Cystathionine beta-synthase

377 ± 22* (14.1)

194 ± 16* (4.9)

nd

nd

GFAP

483 ± 64 *(19.4)

182 ± 13* (4.3)

629 ± 115

nd

Thyroid hormone receptor alpha

618 ± 73*(26.1)

234 ± 24* (6.9)

nd

nd

Tyrosine kinase binding protein

254 ± 6* (7.9)

161 ± 7* (3.3)

nd

nd

“*” Data in BOLD are significantly more highly expressed in amyloid-containing regions than
amyloid-free regions of transgenic mice. nd: not determined
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FIGURE 1. Gene expression profile of transgenic mice in amyloid-containing and
amyloid-free brain regions by qRT-PCR.
The differential expression (transgenic expression relative nontransgenic
expression) is presented for genes that are down-regulated in transgenic
animals and primarily postsynaptic (left half of figure) and those that are stably
expressed and largely presynaptic (right half of figure). The relative expression in
the amyloid-containing region (hippocampus; black bars) and amyloid-free region
(cerebellum; gray bars) are shown when both regions were analyzed. These
regions are also designated in the line to the right of "Aß plaques" with a "+"
beneath the bar indicating amyloid-containing region or a "-" beneath the bar
indicating an amyloid-free region. Following qRT-PCR, each gene transcript level
for each sample is first normalized to the 18S RNA level measured from the
same reverse transcription. For each region, relative expression was determined
by dividing each transgenic value by the average of the non-transgenic values.
The relative expression values for the amyloid-containing and amyloid-free
regions could also be compared statistically to determine if the reduction in
expression was different in the two structures. The values represented in this
figure are the mean + SEM . We did not determine cerebellum measurements for
several genes that were unaffected in the hippocampus of the transgenics, as
indicated by "N.D." in the place of the bar on the figure. “*” indicates significant
differences between APP+PS1 mice and non-transgenic littermates (p < 0.05).
"†" above the bracket indicates transgene associated down-regulation to a
greater extent (P < 0.05) in the amyloid-containing than the amyloid-free regions.
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FIGURE 2. Gene expression profile of Alzheimer disease tissue in amyloidcontaining and amyloid-free brain regions by qRT-PCR.
The differential expression (Alzheimer relative to age-matched normals) is
presented for genes that are primarily postsynaptic (left half of figure) and those
that are primarily presynaptic (right half of figure). The relative expression in the
amyloid-containing region (temporal cortex; area 21; black bars) and amyloidfree region (cerebellum; gray bars) are shown when both regions were analyzed.
These regions are also designated in the line to the right of "Aß plaques" with a
"+" beneath the bar indicating amyloid containing region or a "-" beneath the bar
indicating an amyloid-free region. Following qRT-PCR, each gene transcript level
for each sample is first normalized to 18S RNA measurements from the same
reverse transcription. For each region, relative expression was determined by
dividing each Alzheimer sample value by the average of the age-matched normal
values. The relative expression values for the amyloid-containing and amyloidfree regions could also be compared statistically to determine if the reduction in
expression was different in the two structures. The values represented in this
figure are the mean + SEM. We did not determine cerebellum measurements for
several genes as indicated by "N.D." in the place of the bar on the figure. “*”
indicates significant differences between Alzheimer and age-matched normals (p
< 0.05).

"†" above the bracket indicates disease associated down-regulation to

a greater extent (P < 0.05) in the amyloid-containing than the amyloid-free
regions.
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ABSTRACT
Mice transgenic for mutated forms of the amyloid precursor protein (APP)
plus presenilin-1 (PS1) genes (APP+PS1 mice) gradually develop memory
deficits which correlate with the extent of amyloid deposition. The expression of
several immediate-early genes (IEGs: Arc, Nur77 and Zif268) and several other
plasticity-related genes (GluR1, CaMKIIα and Na-K- ATPase αIII) critical for
learning and memory was normal in young APP+PS1 mice preceding amyloid
deposition, but declines as mice grow older and amyloid deposits accumulate.
Gene repression was less in APP+PS1 mouse brain regions that contain less Aβ,
and in APP mice compared to APP+PS1 mice, further linking the extent of
amyloid deposition and the extent of gene repression. Critically, we
demonstrated that amyloid deposition led specifically to impaired induction of the
IEGs with no effects on basal expression using exposure to a novel environment
30 minutes prior to sacrifice to induce IEGs. These data imply that Aβ deposition
can selectively reduce expression of multiple genes linked to synaptic plasticity
and provides a molecular basis for memory deficiencies found in transgenic APP
mice and, most likely, in early stage Alzheimer's disease (AD). Presumably,
pharmacological agents blocking the Aβ-related inhibition of gene expression will
have benefit in AD.
Keywords: Alzheimer’s, Induction, Immediate-early genes, Transgenic, Amyloid,
Plasticity
Running Title: Amyloid Suppresses Memory-Related Gene Induction
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INTRODUCTION
Mutations in the amyloid precursor protein (APP) and presenilin-1 (PS1)
genes accelerate Aβ deposition and lead to an aggressive form of early-onset
Alzheimer’s disease (AD; Selkoe 2001) Mice transgenic for the mutant forms of
the human APP (Hsiao et al. 1996) and PS1 (Duff et al. 1996) genes have been
bred to generate a viable doubly transgenic mouse presenting accelerated
amyloid pathology (APP+PS1 mice; Holcomb et al. 1998). Despite the lack of
intracellular fibrillary tangles and neuronal degeneration, these mice do exhibit
anterograde amnesia and increased neuro-inflammation with age, providing a
good model for the study of amyloid-associated memory loss at a stage of
pathology similar to that in early AD (Mukaetova-Ladinska et al. 2000;Morgan et
al. 2000;Gordon et al. 2002;Arendash et al. 2001).
Based on work involving DNA microarray comparisons, we previously
described the down-regulation of several genes in 18+ month-old APP+PS1 mice
using quantitative real-time RT-PCR (qRT-PCR; Dickey et al. 2003). Of particular
interest was a panel of down-regulated immediate early genes (IEGs) implicated
in memory function, such as Zif268 (Hall et al. 2000;Miyashita et al. 1998) and
activity-regulated cytoskeletal-associated protein (Arc; Guzowski et al. 2001). We
demonstrated that several more synaptic genes were also selectively downregulated in the amyloid-containing hippocampus of APP+PS1 mice (e.g. the
ionotropic glutamate receptor 1 (GluR1) and Na, K ATPase αIII), while other vital
synaptic mRNAs remained unchanged (e.g. synaptophysin and growthassociated protein 43 (Gap43)).
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Our earlier work found that in most instances, gene expression in
APP+PS1 mice was normal in the amyloid free cerebellum. Here, we describe
additional studies to test the linkage between amyloid deposition and
suppression of these genes, and address whether the diminished IEG expression
is due to reduced basal expression or impaired induction.

MATERIALS & METHODS
Mice were bred in our facility and genotyped using previously described
methods (Gordon et al. 2002). For most experiments, each mouse was
individually transported out of the vivarium to a holding room 30 minutes before
sacrifice. Mice were deeply anesthetized with pentobarbitol (100 mg/kg) and
perfused transcardially with 0.9% saline. Brains were quickly removed and
regions dissected and frozen on dry ice. We have shown previously that the
behavior and amyloid burden of 18 month-old APP+PS1 mice were significantly
different from the non-transgenic littermates used for these studies (Austin et al.
2003).
IEGs were induced by exposure to a novel environment. Fourteen mice
(six 18 month-old APP+PS1 and eight age-matched non-transgenic littermates)
were handled and weighed for three consecutive days to acclimate them to the
holding room and the experimenter. On the fourth day, the mice were placed into
a 0.6m x 0.6m Plexiglas open field containing objects for the mice to investigate
or crawl through for 5 minutes. All mice actively explored this environment and no
differences between transgenic and non-transgenic mice could be discerned in
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the notes taken by the experimenter. After 5 minutes, the mice were placed into a
new cage located in a different room from their home cage for 30 minutes to
avoid disturbing other mice. Following this 30 minute period, mice were killed as
described above. The novel environment was cleaned with 30% ethanol between
mice. To ascertain basal expression levels of IEGs, 14 other mice (six 18 monthold APP+PS1 and eight age-matched non-transgenic littermates) from the same
cohort were removed from their home cage and killed with no delay.
Total RNA was prepared from dissected brain tissue of APP only, PS1
only and APP+PS1 mice along with non-transgenic littermates as previously
described (Dickey et al. 2003). Briefly, total RNA samples were reverse
transcribed (RTed) with MMLV reverse transcriptase and 1M betaine. A standard
curve was established by transcribing increasing amounts of total RNA (covering
3 logs) from an RNA pool compiled from all samples used in that experiment.
Two mass quantities (10 & 2ng) or, in later experiments, a single mass quantity
of 5ng of total RNA from each sample were RTed for comparison to the standard
curve.
Primer pairs for qRT-PCR were generated from the web-based
applications Primer3 and the Oligo Toolkit (Operon). Experimental wells
containing 25µl PCR reactions were run in triplicate in 96-well plates. Two-step
PCR was run on the MJ Research Opticon (Boston, MA) as follows; 1 cycle of
95˚C for 15 minutes followed by 40 cycles of 95˚C for 15 seconds and 60-65˚C
for 1 minute. All primer pairs amplified a single peak of fluorescence by melt
curve analysis. The standard curve was calculated by plotting the threshold cycle
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(Ct) against the log nanogram (ng) quantity of RNA added to the RT reactions.
PCR efficiency varied by less than 5% for all amplicons. A linear regression was
performed and the slope, relating Ct to log ng RNA, was calculated, and
converted to a mass quantity of standard RNA. These mass values for the genes
of interest were then divided by 18S ribosomal RNA mass values of the same RT
reaction to determine fold-change in expression relative to the standard RNA
pool. We chose 18S rRNA as the endogenous control gene based on empirical
data of our own and results from others (Schmittgen and Zakrajsek 2000)
indicating that other commonly used house-keeping genes such as β-actin and
GAPDH have more variable expression in tissue, particularly brain, while 18S
remained steady. These fold change values for samples in the experimental and
control groups were analyzed for significance using 1-way ANOVAs (Dickey et al.
2003). For the mice in the behavioral induction study a 2-way ANOVA was
performed with the main variables being genotype and induction state.

RESULTS
Quantitative RT-PCR analysis of hippocampal tissue from APP+PS1 mice
at 2, 6 and 18 months of age revealed decreases in specific mRNA transcripts
with increased amyloid accumulation. At 2 months of age, prior to development
of cerebral amyloid, no loss of mRNA expression was seen for any marker (Figs
1A & B). However, by 6 months of age, the IEGs Nur77 (a nuclear orphan
receptor), Arc and Zif268 were significantly under-expressed by 35, 40, and 22%,
respectively, compared to non-transgenic littermates (Fig 1A). By 18 months, in
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addition to further reduced IEG expression, GluR1, calcium/calmodulin kinase IIα
(CaMKIIα) and Na, K ATPase αIII mRNA expression was significantly reduced by
20-30% (Fig 1B). Synaptophysin and Gap43 remained unchanged throughout
the lifespan of the transgenic mice. The findings herein also revealed two distinct
patterns in gene regulation. The early decrease in IEG expression at 6 months in
the APP+PS1 mice (Fig 1A) is contrasted by the later reduction in the more
constitutively expressed plasticity genes GluR1, CaMKIIα and Na, K ATPase αIII
seen at 18 months (Fig 1B). Figure 1C was generated by averaging the individual
sample percent reduction values for each gene, then averaging these according
to IEG, plasticity-related or non-changing synaptic category and doing one-way
ANOVA on these values to determine significance. This figure demonstrates that
a significant reduction at 6 months is only seen with the IEGs when analyzed in
this manner, while at 18 months both IEG and plasticity-related gene expression
was significantly reduced.
To further understand the relationship between amyloid deposition and
mRNA expression, we investigated the gene expression of 18 month-old singly
transgenic APP or PS1 mice compared to mice expressing both APP+PS1
transgenes. The amyloid-free PS1 transgenic mice had no changes in
expression of any genes (Fig 2). However, the singly transgenic APP mice
exhibited significant 30-40% loss of the IEGs Nur77, Arc and Zif268, without
significant loss of the more constitutively expressed synaptic proteins GluR1,
CaMKIIα and Na, K ATPase αIII (Fig 2).
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A regional analysis was then performed on 18 month-old APP+PS1 mice,
comparing gene expression levels in the hippocampus, posterior cortex and
caudate nucleus (striatum). In the posterior cortex, APP+PS1 mice had a
significant reduction in the IEGs, however the other plasticity-related genes,
GluR1 and Na, K ATPase αIII remained unchanged (Fig 3). CaMKIIα was also
significantly reduced, but not to the same extent as in the hippocampus (Fig 3).
Caudate nucleus analysis revealed a similar pattern of expression; significantly
reduced IEGs (25-35%) without reductions in the other plasticity-related genes
(Fig 3). For all genotypes and brain regions, Gap43 and synaptophysin
expression was unaltered (Figs 2& 3).
To determine whether the reduction of the IEGs in the memory-deficient
APP+PS1 mice was a result of lower basal expression level or decreased
experience-dependent induction, we exposed 18 month-old APP+PS1 mice and
their non-transgenic littermates to a novel environment for 5 minutes followed by
30 minutes in a new cage. This manipulation provided the means to increase IEG
expression, resulting in increased representative mRNA levels (see methods
above). For the non-induced (basal) control groups, additional 18 month-old
APP+PS1 mice and their non-transgenic littermates were taken from their home
cage and rapidly killed. Upon analyzing the hippocampi of these mice by qRTPCR, we found that there was a significant 2.5 fold induction of IEGs in our
behavioral paradigm in non-transgenic mice (Fig 4). This induction was
significantly blunted by half for Arc and Nur77 in the APP+PS1 mice compared to
induced non-transgenic littermates (Fig 4). The basal expression of the IEGs was
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nearly identical in the two genotypes (Fig 4). Zif268 expression was also induced
significantly by the environmental novelty, but suppression of its induction in
APP+PS1 mice was not statistically significant. The other plasticity-related
genes, GluR1, CaMKIIα and Na, K ATPase αIII were not induced by exposure to
the novel environment. However these genes did have significantly reduced
expression when analyzed by genotype, while Gap43 and synaptophysin
remained unaffected by genotype or exposure to a novel environment (Table 1).
Glial fibrillary acidic protein (GFAP) mRNA increased in the hippocampi of
APP+PS1 mice. At 2 months, GFAP was unchanged, by 6 months it was
increased by 80% and at 18 months levels increased to over 300% that of nontransgenic littermates (data not shown), demonstrating the potential role for glial
cells in the pathogenesis of amyloid-associated dementias and confirming earlier
ELISA and histochemical results in APP+PS1 mice (Morgan et al. 1991;Gordon
et al. 2002). We have also increased the breadth of our investigations into gene
expression by analyzing many more genes, finding that several more remain
unaltered in the 18 month-old APP+PS1 hippocampus compared to nontransgenic littermates. These include Ha-Ras, Rheb, Shank3, synapsin,
microtubule-associated protein 2 (MAP2), the Na, K ATPase γ subunit and the
two metabotropic glutamate receptors, mGluR1 and mGluR5. These findings
reiterate the selectivity of gene dysregulation associated with either amyloid
deposition itself or its subsequent deleterious effects on the brain.
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DISCUSSION
Post-mortem brain tissue from AD patients is riddled with amyloid plaques
comprised of Aβ peptide polymers and intracellular neuro-fibrillary tangles of
hyperphosphorylated tau filaments. Neuron loss and gliosis are also evident. The
cognitive impairments of the disease could be attributed to any combination of
these pathologies, and recent evidence supports each of these components. The
development and subsequent usage of transgenic animal models expressing
genes known to produce AD-like pathology have provided a way to elucidate the
contributions of these individual pathological features. Here, we have utilized the
memory-deficient APP+PS1 mouse model to analyze expression of genes that
appear to be essential for the formation of memories. Using qRT-PCR, we have
found that as amyloid becomes reliably detectable in the brains of the APP+PS1
mice (6 mos.), IEGs begin to realize decreased expression. As amyloid burden
increases, resulting in further gliosis and onset of memory loss, several other
more constitutively expressed genes critical for plasticity and memory function
are significantly reduced. Perhaps of greatest significance here is the finding that
the induction of the IEGs was significantly impaired, indicating that the triggering
mechanism for their rapidly increased expression is being inhibited somehow in
these mice that develop amyloid. These data provide strong support for the
hypothesis that amyloid, itself, impairs the induction and expression of genes
thought to be essential for retaining newly acquired information.
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Our first indication that amyloid might repress genes essential for memory
came via a microarray study (Dickey et al. 2003). Intrigued by the novelty of the
idea that amyloid may suppress molecular mechanisms for memory, independent
of neuron or synapse loss, we examined other memory associated genes and as
of this writing have found 11 that are down-regulated. For these studies, we
chose a representative panel of these down-regulated genes associated with
LTP and memory consolidation, 3 of which are immediate early (inducible) genes
(Arc, Nur77 & Zif268) and 3 with more constitutive expression (Na, K ATPase
αIII, GluR1 and CaMKIIα). Mice receiving antisense oligonucleotides targeting
the mRNA of Arc, an IEG that is translated at the synapses (Lyford et al. 1995),
have disrupted LTP maintenance and demonstrate impaired long-term memory
(Guzowski et al. 2000). Nur77 mRNA, also an IEG product, is the transcript for
an orphan thyroid hormone receptor that is dramatically increased in response to
several excitotoxic stimuli (Watson and Milbrandt 1989;St Hilaire et al. 2003).
Zif268 is a zinc finger transcription factor that is rapidly up-regulated in the
hippocampus of rats after exposure to a novel stimulus (Hall et al. 2000) and by
water maze training (12). Additionally, homozygous Zif268 knockout mice exhibit
long term-term memory deficits (Jones et al. 2001) underscoring the critical
nature of this gene to proper cognitive function. The Na, K ATPase αIII subunit,
when inhibited by oubain, is known to disrupt memory consolidation (Watts and
Mark 1971;Mark and Watts 1971). Recent reports have implicated the ionotropic
glutamate receptor GluR1 (AMPA1) as essential for various forms of synaptic
plasticity and memory retention (Schmitt et al. 2003;Lee et al. 2003). CaMKIIα, is
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also thought to be critical for memory retention, as evidenced by mice transgenic
for activated forms of the protein having impaired memory retention (Mayford et
al. 1995;Mayford et al. 1996). Expression of both the growth associated protein,
Gap43, a gene important for growth cone formation as well as memory
(Routtenberg et al. 2000), and synaptophysin, a protein widely used as a marker
for nerve terminals, remains unchanged in the APP+PS1 mouse brain. Thus, not
all genes involved in synaptic function or plasticity are down-regulated by Aβ
deposits.
To understand the contribution of amyloid to the dysregulation of gene
expression in the APP+PS1 mice we analyzed hippocampal tissue from 2 monthold mice, an age prior to amyloid deposition (Gordon et al. 2002), 6 month-old
mice, when amyloid deposits are just beginning to form, and 18 month-old mice,
when there is considerable amyloid in the forebrain (Gordon et al. 2002).
Critically, the stable expression of all genes analyzed at 2 months (Fig 1), an age
when APP and PS1 over-expression is present, but amyloid deposits have not
yet appeared, argues that transgene expression per se is not the cause of the
reduced expression. It is the accumulation of amyloid that appears to be
regulating expression in such a way that some genes, predominately the IEGs,
are diminished when amyloid deposits are still low (6 mos.) while others (e.g.
GluR1 and Na, K ATPase αIII) are only affected when amyloid deposition is
substantial (18 mos.). CaMKIIα expression is significantly decreased at 6 months
although not to the same degree as the IEGs. This could possibly indicate that
CaMKIIα is one of the first genes being affected by the presence of excess
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amyloid in the brain, which is significant due to its involvement in the calcium
signaling cascade thought to mediate receptor activated transcription (Blanquet
et al. 2003). As summarized in figure 1C, these findings provide evidence that
slightly reduced IEG expression is not sufficient to cause memory impairments,
but, assuming that protein expression of these genes follows that of their mRNA,
the additional down-regulation of these more constitutively expressed plasticityrelated genes, as detected at 18 mos., may be necessary to disrupt memory.
This emphasizes the robustness of mnemonic processes (or the lack of
sensitivity of behavioral tests), as only when partial inhibition of the expression of
multiple genes are present in aggregate are memory deficits readily apparent.
The APP only mice have roughly one third of the Aβ deposition as
APP+PS1 mice (Jaffar et al. 2001), while the PS1 mice resemble non-transgenic
mouse brain when analyzed for amyloid burden and amyloid associated
pathogenesis. Our findings in figure 2 reveal that the singly transgenic APP mice
also have reduced IEG expression without reductions in the other plasticityrelated genes, while the PS1 singly transgenic mice do not have reductions in
either set of genes. This is consistent with the selective impairment of IEG
expression found at 6 mos.
We had previously shown that gene expression in the cerebella of
APP+PS1 mice, a region without detectable amyloid levels, remained unchanged
when compared with non-transgenic littermates (Dickey et al. 2003).
Subsequently, we analyzed two additional regions of the forebrain in 18 monthold APP+PS1 mice; posterior cortex, a region with fewer amyloid plaques than
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the hippocampus, and the caudate nucleus, a brain region that does not
accumulate fibrillar amyloid plaques, yet has abundant diffuse Aβ (Gordon et al.
2002). Interestingly, upon analysis of both of these regions, we found that like the
APP singly transgenic mice and the 6 month-old APP+PS1 mice, only the IEGs
were significantly under-expressed. Similar to the 6 month-old APP+PS1 mice,
CaMKIIα was slightly down-regulated in the posterior cortex but not as
dramatically as in the hippocampus. Again, this is consistent with the relative
amyloid burden associated with these two conditions. Perhaps most significant is
the finding that the caudate nucleus, which only contains diffuse Aβ, still has
reduced IEG expression. This further implicates Aβ itself, rather than a mediator
of neuro-inflammation, as the precipitator of this mRNA reduction. These findings
again argue that the IEGs are very sensitive to the presence of amyloid, possibly
indicating a direct interaction of the amyloid peptide with some mechanism
regulating the expression of these genes.
One final critical issue in this investigation was the nature of the reductions
seen in IEG expression. These genes are expressed at low levels when mice are
in a resting state. However, upon induction by some stimulus (e.g. maximal
electroconvulsive shock (MECS; Cole et al. 1990) or a novel environment
(Guzowski et al. 2001) there is a rapid and robust increase in their expression, at
which point they have dramatic effects on synapse structure and properties. This
increase is transient so that within minutes to hours, some IEGs return to their
basal expression level. By using a novel environment, in which mice were
allowed to investigate several new objects for 5 minutes, we were able to
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demonstrate a significant induction of the IEGs Arc, Nur77 and Zif268. We
selected a 30 minute duration as the time point because previous studies have
shown that Arc and Nur77 reach a maximal level of expression by 30 minutes
and begin to return to basal levels after 1 hour (Lyford et al. 1995;Tang et al.
1997). We felt that genes that were induced maximally would provide us the
greatest opportunity to see any significant reductions in their expression.
Previous studies have indicated that zif268 mRNA has a slightly greater half-life
than other IEG RNAs (Guzowski et al. 2000;Guzowski et al. 2001) which would
effectively increase basal levels, making it more difficult to detect differences due
to a single behavioral event, possibly explaining the reason we were unable to
see significant reductions in its expression. We had suspected that our standard
transport and handling procedures prior to killing the mice were sufficient to
induce the IEGs. Anticipating this, our standard protocol is to retrieve each
mouse from the vivarium 30 minutes before pentobarbitol injection. The finding
that only the induction of these genes was impaired in APP+PS1 mice confirms
these suspicions. These observations emphasize the need to control the
conditions leading up to euthanasia in studies of gene expression in brain.
These data, when taken together with the findings that Aβ is precipitating
reductions in gene expression, indicate that in amyloid-depositing APP+PS1
mice, the ability to induce IEG expression is suppressed. This suppression may
be a direct effect of Aβ on a receptor altering signal transduction cascades
(possibly the Ras/MAPK pathway or the Ca++ signaling cascade (Dineley et al.
2001)). Alternatively, Aβ deposition may impair increases in general synaptic
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activity presumed to result from exposure to environmental novelty, leading to
less induction of these activity dependent IEGs. The diminution of Na, K ATPase
activity may permit normal resting activity in neurons, but lead to failure when
demands for ion pumping increase with elevated synaptic activity. Another
possibility remains that these events are secondary to increased inflammation
associated with glial activation, particularly given the considerable effects that
cytokines can have on gene expression. However, at least for the IEGs this
seems unlikely, as microglial activation and cytokine production are low in 6
month APP+PS1 mice, when the IEGs are already realizing significant decreases
(Fig 1A & C; (Gordon et al. 2001;Benzing et al. 1999;Mehlhorn et al. 2000).
Ultimately, the data presented here point to Aβ, or some direct effect of its
presence in the brain, as the causal agent for suppressed induction of IEG
expression.
The failure to identify reduced expression of rheb in APP+PS1 mouse
hippocampus provides an example of one IEG that does not seem to be
influenced by the presence of Aβ. Shank3, involved in formation of the postsynaptic density (Boeckers et al. 2002), along with calsyntenin-1 and
synaptopodin (Dickey et al. 2003), also remain unchanged in the APP+PS1
mouse, eliminating the possibility of a generalized but exclusive loss of postsynaptic mRNAs, with axon terminals remaining intact and functional. Also, the
two dendritic metabotropic glutamate receptors, mGluR1 and mGluR5, that have
been linked to memory formation and LTP-maintenance (Riedel et al. 2000), do
not exhibit significant decreases (Petersen et al. 2002). Other genes with
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unchanged expression are MAP-2, thought to propagate growth cone formation
of the axon (Gordon-Weeks 1991) and the Na, K ATPase γ subunit, which
modulates the activity of the ATPase α subunit (Crambert and Geering 2003),
demonstrating a specific reduction in the catalytic α subunit expression level. The
stability of these other markers emphasizes the significance of those genes that
do suffer from amyloid-related repression.
The recent finding by Hock et al. that vaccination with the amyloid peptide
stabilized and, in some cases, improved cognitive ability in humans suffering
from AD (Hock et al. 2003), argues that Aβ itself likely plays in the development
of memory dysfunction in AD beyond the effects on neuronal and synapse loss.
The data presented here provide new evidence to support the idea that Aβ
impedes the induction of genes critical for synaptic plasticity. The APP+PS1
transgenic mouse model, therefore, provides a means with which to understand
how amyloid diminishes the functioning of essential memory-related molecular
systems within the neuron. There is a dynamic nature of specific neuronal
transcripts that lend to the ability of the brain to retain information and it seems
that amyloid disrupts this system in multiple ways. It is possible that as the IEG
induction decreases, it reaches a point at which the strength of the subsequent
memory trace is inadequate to modify the mouse’s behavior. It has already been
shown in multiple mouse models that amyloid deposition is associated with the
decline of cognitive function (Chen et al. 2000;Gordon et al. 2001;Westerman et
al. ;Heikkinen et al. 2002). These data provide the first hints of a molecular basis
for this problem. The results herein suggest potential targets for therapy and
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prophylaxis of amyloid-associated dementias and possibly other forms of
cognitive impairments that are to this point poorly understood at the level of gene
expression.
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FIGURE 1. Time course of gene expression in the hippocampus of transgenic
mice by qRT-PCR.
Panel “A” shows the differential expression (transgenic expression (n=7-8
APP+PS1) relative to non-transgenic expression (n=7-8 Non-Tg; set as 100% for
each gene) for three IEGs (Arc, Zif268 and Nur77) that were 1) unaffected at 2
months, prior to amyloid development, 2) significantly down-regulated in
transgenic animals by 6-months of age, and 3) further down-regulated by 18
months. Synaptophysin remained equivalent to non-transgenic animals
throughout their lifespan. Panel “B” shows the differential expression for a set of
plasticity-related genes (CaMKIIα, GluR1, and Na, K ATPase αIII) that were
unchanged at both the 2 and 6 month time points, with the exception of CaMKIIα
at 6 months. However, by 18 months these genes were all significantly down
regulated. Gap43 remained equivalent to non-transgenic animals throughout
their lifespan. Panel “C” summarizes these findings by averaging the values for
each gene into the representative category and analyzing these for significance
by one-way ANOVA. The values represented in this figure are the mean + SEM.
“*” indicates significant differences between APP+PS1 mice and non-transgenic
littermates (p < 0.05).
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FIGURE 2. Gene expression in hippocampi of APP only, PS1 only and APP+PS1
transgenic mice at 18 months of age by qRT-PCR.
This figure compares expression of doubly transgenic APP+PS1 mice and
age-matched single transgenics with non-transgenic littermates. Black bars
indicate PS1 only mice, gray bars indicate APP only mice and white bars indicate
APP+PS1 mice. The far left panel describes the differential expression
(transgenic expression (n=7-8 APP+PS1) relative to non-transgenic expression
(n=7-8 Non-Tg; set as 100% for each gene) for Arc, Zif268 and Nur77. These
genes were down-regulated in both APP only and APP+PS1 transgenic animals,
however the PS1 only transgenics had no deficits in expression. The center
panel reveals that the plasticity-related genes CaMKIIα, GluR1, and Na, K
ATPase αIII were down-regulated at 18 months only in the APP+PS1 transgenic
mice, while APP only and PS1 only expression remained equivalent to that of
non-transgenics. The right panel demonstrates the specificity of this effect by
showing that other synaptic genes were not influenced by genotype in any of the
3 transgenic models. Expression values for the APP only and APP+PS1
transgenics could also be compared statistically to determine if the differing
levels of expression were significant between the two models. The values
represented in this figure are the mean + SEM. “*” indicates significant
differences between APP+PS1 mice and non-transgenic littermates (p < 0.05).
"†" above the bracket indicates differences (P < 0.05) in expression between
APP+PS1 mice and APP only mice.
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FIGURE 3. Gene expression profile in hippocampus, posterior cortex and
caudate nucleus of APP+PS1 transgenic mice at 18 months of age by qRT-PCR.
This figure compares gene expression in three different brain regions of
doubly transgenic APP+PS1 mice with non-transgenic littermates. Black bars
indicate caudate nucleus (CN), gray bars indicate posterior cortex (CX) and white
bars indicate hippocampus (HC) in APP+PS1 mice. The far left panel describes
the differential expression in each brain region (transgenic expression (n=7-8
APP+PS1) relative to non-transgenic expression (n=7-8 Non-Tg; set as 100% for
each gene) for Arc, Zif268 and Nur77. These genes were significantly downregulated in all three regions. The center panel reveals that the plasticity-related
genes CaMKIIα, GluR1, and Na, K ATPase αIII were down-regulated at 18
months only in the HC of APP+PS1 transgenic mice, with the exception of
CaMKIIα which is significantly down-regulated in the CX. The right panel
demonstrates the specificity of this effect by showing that other synaptic genes
were not influenced in any of the brain regions. Expression values for the HC and
CX could also be compared statistically to determine if the differing levels of
expression were significant between the two regions. CN was not compared, as
these values were even closer to non-transgenic than those of CX. The values
represented in this figure are the mean + SEM. “*” indicates significant
differences between APP+PS1 brain regions and those of non-transgenic
littermates (p < 0.05). "†" above the bracket indicates differences (P < 0.05) in
expression between PCX and HPC of APP+PS1 mice.
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FIGURE 4. IEG expression measured by qRT-PCR in hippocampi of APP+PS1
transgenic mice and non-transgenic littermates following Induction by
environmental novelty.
This figure compares expression of IEGs between APP+PS1 mice and
non-transgenic littermates either following induction by a 5 minute exposure to a
novel environment with a subsequent 30 minute period in a new cage, or
immediate euthanitazation after removal from their home environment. White
bars indicate those mice that were euthanatized quickly to measure basal
expression. Black bars indicate those animals that were exposed to
environmental novelty to measure induced expression. ANOVA indicated a
significant effect of induction for Arc (F= 38.8; P < 0.0001), Nur77 (F= 26.1; P <
0.0001), and Zif268 (F= 27.992; P < 0.0001). There was also a significant
interaction between genotype and induction for Arc (F= 4.4; P < 0.05) and Nur77
(F= 4.3; P < 0.05), but not Zif268. The values represented in this figure are the
mean + SEM. “*” indicates a significant interaction effect between genotype and
treatment (p < 0.05) as determined by two-way ANOVA.
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TABLE 1. Expression of non-inducible genes in APP+PS1 mice stimulated by
environmental novelty compared to non-transgenic littermates by qRT-PCR.
Values indicate percent reduction in APP+PS1 mouse hippocampus RNA
expression compared to non-transgenic littermates’ ± SEM. No induction
occurred for these genes, therefore mice were analyzed by genotype only using
one-way ANOVA. “*” indicates significantly different from non-transgenic mice at
P<0.05.
Gene
Properties
PlasticityRelated Genes
Non-Changing
Synaptic
Genes

Marker mRNA

Non-Induced

CaMKIIα
GluR1
Na, K ATPase αIII
Gap43

87.3 ± 5.2*
83.8 ± 6.6*
83.3 ± 5.9*
95.6 ± 4

Synaptophysin

95.4 ± 5.1
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ABSTRACT
The pathology of Alzheimer’s disease (AD) is comprised of extracellular
amyloid plaques, intracellular tau tangles, dystrophic neurites and
neurodegeneration. The mechanisms by which these various pathological
features arise are under intense investigation. Here, based on pilot gene
expression studies, we have further analyzed the relationship between Na+/K+
ATPase and amyloid using the APP+PS1 transgenic mouse model. We report
that in addition to decreased mRNA expression, there is decreased overall
activity of the enzyme specifically in the amyloid-containing hippocampi of the
APP+PS1 mice. In addition, dual immunolabeling reveals an absence of Na+/K+
ATPase protein in a circumferential zone near congophilic plaques that is
occupied by dystrophic neurites. We also demonstrate that cerebral Na+/K+
ATPase activity can be directly inhibited by high concentrations of Aβ. In AD, the
local concentration of Aβ within the immediate vicinity of plaques may inhibit
Na+/K+ ATPase activity. Loss of ionic homeostasis may result in synaptic edema
and the appearance of dystrophic neurites. It might also be expected that the
electrotonic properties of processes would be modified by loss of ionic balance,
leading to disruption of synaptic integration and, conceivably, learning and
memory. Therapies aimed at maintaining osmotic balance by enhancing Na+/K+
ATPase activity in early stage AD may delay the disease’s progression.
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INTRODUCTION
Alzheimer’s disease (AD) has several well characterized post-mortem
pathological markers that include both gliosis and dystrophic neurites
surrounding extracellular amyloid plaques. In addition, intracellular tangles of
hyper-phosphorylated tau and massive neurodegeneration are seen later in the
disease process. Mutated forms of both amyloid precursor protein (APP) and
presenilin 1 (PS1) leads to an increased rate of amyloid deposition and therefore
an earlier onset of the dementia associated with AD (Selkoe, 2001). Doubly
transgenic mice expressing these human mutants of the APP (Hsiao et al., 1996)
and PS1 (Duff et al., 1996) genes (APP+PS1 mice; Holcomb et al., 1998) exhibit
a tremendous amount of amyloid deposition and gliosis without the formation of
tangles or neuron loss, and yet they still develop anterograde amnesia as they
age, similar to what is seen in the early stages of AD (Morgan, 2003). Memory
deficits without the loss of neurons indicate that amyloid-associated disruption of
some step in neural processing can result in memory deficits.
Previously we have described decreased expression of genes critical for
learning and memory and impaired induction of several immediate early genes
(IEGs) in aged, memory deficient APP+PS1 mice (Dickey et al., 2003;Dickey et
al., 2004). Increased neural activity during learning is argued to be a primary
inducing stimulus for these IEGs (Dragunow, 1996). One possible mechanism to
describe this phenomenon would be that amyloid is diminishing the ability of
neurons to facilitate sufficient electrical signaling to induce changes in synaptic
plasticity essential for memory consolidation. Here we present evidence that in
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addition to a decreased level of Na+/K+ ATPase mRNA, the activity of this
enzyme is significantly decreased in the APP+PS1 hippocampus but not in the
amyloid-free cerebellum, an important finding as ouabain administration has
been shown to impair memory consolidation (Watts and Mark, 1971; Mark and
Watts, 1971). We decided to investigate further the interactions of Aβ and
Na+/K+ ATPase activity to understand better the role of this enzyme in AD and
memory dysfunction.

MATERIALS AND METHODS
Tissue Preparation
Mice were bred in our facility and genotyped using previously described
methods (Gordon et al., 2001). The working memory performance of the
APP+PS1 mice used in these studies was impaired when compared to nontransgenic littermates as published previously (Austin et al., 2003; untreated
groups were studied here). Briefly, 17-18 month old mice were deeply
anesthetized with pentobarbital (100 mg/kg) and perfused transcardially with
phosphate buffered saline. Brains were removed and halved into right and left
hemispheres. The right hemisphere was immediately dissected into regions and
frozen on dry ice, while the left hemisphere was post-fixed in 4% paraformaldehyde for 24 hours and subsequently processed through a cryoprotection schedule of 10, 20 and 30% sucrose. Frozen brains were sectioned
horizontally on a sliding microtome at 25 µm and stored in Dulbecco’s phosphate
buffered saline plus azide at 4° C.
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Real time RT-PCR Analysis
As previously described, real time RT-PCR was used to measure
expression levels of mouse Na+/K+ ATPase αIII (NAK3) mRNA from total RNA
extraction of both hippocampus and cerebellum tissue (Dickey et al.,
2003;Dickey et al., 2004). 18S ribosomal RNA was used as the stably expressed
denominator across tissue samples. The following primers for NAK3 were
designed using the mouse sequence from the NCBI accession number
NM_144921: Forward primer 5’ CAA GAA GAG CAA GGC CAA AG 3’ and
reverse primer 5’ TTG TAT TTC CGG CAG ACC TC 3’. The sequences for the
18S rRNA primers were acquired from Schmittgen and Zakrajsek (2000).

Na+/K+ ATPase Activity Assay & Amyloid Preparation
An assay to detect specific activity of Na+/K+ ATPase by measuring the
release of phosphate was developed using a variation of the method described
by Ellis et al. (2000). Freshly frozen dissected hippocampi and cerebella (2030mg tissue weight) from APP+PS1 and non-transgenic littermates were
homogenized using a rotor-stator homogenizer in 1 ml of cold suspension buffer
containing 85mM NaCl, 20mM KCl, 4mM MgCl, 0.2mM EGTA and 30mM
histidine pH 7.2. Saponin was added to the samples to a final concentration of
20µg/ml. They were then incubated at 37°C for 15 minutes and immediately
returned to ice. Protein concentration was measured by Bradford assay and
concentrations were adjusted to 10mg/ml tissue weight.
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In a 96-well plate, 60µl of ATP buffer containing 140mM NaCl, 20mM KCl,
3mM MgCl, 30mM histidine and 3mM ATP were added to wells. Two sets of
samples were setup, one with ATP buffer only and the other with 100µM of the
Na+/K+ ATPase selective inhibitor ouabain added to the ATP buffer.
Subsequently, 10µl of protein homogenates were added to the ATP buffer ±
ouabain, which were then mixed by pipetting and incubated at 37°C for 30
minutes. The reaction was stopped by adding 120µl of an acid molybdate
solution consisting of 0.5g ammonium molybdate (Sigma, St. Louis, MO) in 0.5M
sulfuric acid. After mixing, 10µl of Fiske Subbarow Reducer (Sigma, St. Louis,
MO) was added and wells were mixed again. The plate was allowed to incubate
covered at room temperature for 10 minutes and then measured
spectrophotometrically at 660nm. Specific activity was measured by taking the
difference between samples ± ouabain and, using a standard curve of serially
diluted 4mM phosphoric acid, converting this OD value to µmols of inorganic
phosphate (Pi) liberated/mg protein/ hour. All reactions were performed in
triplicate, which were then averaged to produce the single value for the sample.
Differences between APP+PS1 and non-transgenics were analyzed for
significance using one-way ANOVA.
For analysis of activity inhibition by Aβ, purified active cortical Na+/K+
ATPase (Sigma, St. Louis, MO) was pre-incubated for 2 hours in a 37°C orbital
shaker separately with 112.5, 225 and 450 µg/ml of Aβ 1-42 or vehicle only.
Activity was then measured using the same activity assay as above and
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significance was measured using one-way ANOVA comparing activity between
vehicle treated and Aβ treated.
Aβ used for these studies was generated by resuspending 1mg of
commercially available recombinant Aβ 1-42 peptide (rPeptide, Athens, GA) in
221µl of 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP, Sigma, St. Louis, MO) to
generate 45µg Aβ 1-42 films. These films were resuspended in 2µl of dry DMSO,
followed by agitation and subsequent addition of 48µl of cold water and overnight
incubation at 4°C. This yielded approximately a 900µg/ml suspension of Aβ.
Quality of the peptide was confirmed using SDS-PAGE analysis. 10µl of the
overnight preparation was mixed with 2x sample buffer (62.5mM Tris-HCl, 10%
glycerol, 10% SDS, and 0.1% bromophenol blue), without β-mercaptoethanol or
heat, and loaded onto a 4-20% gradient Tris-glycine gel (Bio-Rad, Hercules, CA)
and run at 100mV for 60-90 minutes. This was followed by an overnight
Comassie Blue stain of the gel and a prolonged destain in water the following
day.

Histology
Immunohistochemical and immunofluorescence analyses for Na+/K+
ATPase α III and phosphorylated neurofilament, respectively, were performed on
the same 25µm free-floating hippocampal sections. Sections were treated 15
minutes with 10% methanol, 10% hydrogen peroxide and 80% PBS to block
endogenous peroxidase activity, and then washed 3 times with PBS. Sections
were subsequently treated with sodium borohydride for 15 minutes to reduce
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background auto-fluorescence (Clancy and Cauller, 1998) followed by washing
with PBS. Sections were then permeabilized for 30 minutes with 100mM lysine,
0.2% triton x-100, 2% goat serum and 2% horse serum in PBS, and washed 3
times with PBS. Sections were then incubated overnight in a 1:300 dilution of
goat F(ab’)2 anti-mouse IgG (Protos Immunoresearch, Burlingame, CA) to block
endogenous mouse IgG. Sections were washed the following day and coincubated with a 1:5000 dilution of a rabbit anti-rat Na+/K+ ATPase α III IgG
(Upstate Biotech, Lake Placid, NY) and a 1:10,000 dilution of a mouse
monoclonal IgG1 ascites pool specific for phosphorylated forms of neurofilament
(SMI-312; Sternberger Monoclonals, Lutherville, MD) in 2% goat serum and 2%
horse serum in PBS. The following day, sections were washed, and then
incubated in both a 1:3000 dilution of anti-rabbit biotinylated secondary antibody
(Vector Labs, Burlingame, CA) and a 1:100 dilution of anti-mouse fluorescein
conjugated secondary antibody (Vector Labs, Burlingame, CA) for 2 hours. After
washing, the tissue was incubated with Vectastain Elite ABC kit (Vector Labs,
Burlingame, CA). The tissue was then washed and stained with a
diaminobenzidine:peroxide system plus nickel enhancement (DAB/Ni2+), followed
by final washes. Compact amyloid plaques were visualized using Congo red
staining after sections were slide mounted and dried (Gordon et al., 2001).
Briefly, slides were incubated in alkaline alcoholic saturated sodium chloride
(AASSC), followed by 0.2% Congo red in AASSC, then dehydrated and coverslipped with xylene-free Vectamount (Vector Labs, Burlingame, CA; other
mounting media were tested, but only Vectamount was suited for both
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immunohistochemistry, immunofluorescence and Congo red staining). The extent
of nonspecific binding was assessed in the absence of primary antibodies for all
assays. Specificity of the Na+/K+ ATPase antibody was confirmed by reduced
staining following a 2 hour pre-incubation of the antibody with purified cerebral
ATPase at a 1 to 4 molecule ratio (1 antibody to 4 protein molecules). Both
immunostains were characterized individually before the co-incubation procedure
was implemented.

Western Blot
Brain homogenate from the activity assay above was equilibrated to 10µg
of total protein. This homogenate, along with 1 mg of purified cerebral Na+/K+
ATPase, was diluted 1:1 with loading buffer containing 4% SDS and 5% βmercaptoethanol, heated to boiling for 5 minutes and loaded onto a 7.5% Trisglycine gel which was then electrophoresed at 100mV for one hour in the
presence of SDS. The protein was subsequently transferred onto an Immobilon
membrane (Millipore, Billerica, MA) for an hour at 100mV. The blot was rinsed
with borate saline + 0.05% Tween-20 (BST) and blocked overnight at 4°C in 5%
non-fat dry milk (NFDM). The following day, a 1:2000 dilution of anti-rat Na+/K+
ATPase αIII antibody (Upstate Biotech, Lake Placid, NY) in 0.5% NFDM+BST
was applied to the blot for 1 hour, followed by washing and a subsequent 1 hour
incubation with a 1:5000 dilution of hrp-labeled anti-rat IgG (Sigma, St. Louis,
MO) in 0.5% NFDM+BST. After washing, the blot was developed for
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chemiluminescence using a luminol substrate kit (Santa Cruz Biotech, Santa
Cruz, CA) and film exposure.

RESULTS
The pathology underlying AD is vast and complex, but through the use of
transgenic models that develop various aspects of the disease, our
understanding of how each pathological feature contributes to the progression of
AD can be improved. Here we have used the APP+PS1 transgenic mouse model
to better understand how the deposition of amyloid and the subsequent
deleterious effects of its presence are contributing to the consistent memory loss
seen in these animals (Morgan et al., 2000;Gordon et al., 2002;Arendash et al.,
2001;Austin et al., 2003). Specifically, we have found that Na+/K+ ATPase, a
protein critical for not only brain function, but survival, is adversely affected by the
presence of amyloid and this interaction may be driving a major pathological
event in the progression of amyloid-associated dementia.
Initial quantitative real-time PCR (qRT-PCR) investigations revealed that
the expression of the Na+/K+ ATPase brain-specific catalytic subunit (α III)
mRNA is significantly (25-30%) decreased in the amyloid rich hippocampus of
memory deficient APP+PS1 mice when compared to both the non-transgenic
littermate hippocampus and the amyloid-free cerebellum of these same doubly
transgenic mice (Figure 1). This supported the notion that amyloid is specifically
altering expression of genes, thereby contributing the inability of these mice to
perform well in a radial arm water maze task. To determine whether the Na+/K+
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ATPase protein itself was being modified in agreement with the reduced mRNA
levels, we initially performed Western blot analysis; however, we found that this
method was not sufficiently sensitive to detect the modest reduction in
expression (data not shown). We turned to a more quantitative approach, using a
colorimetric assay to measure activity of the enzyme. Using ouabain as a
selective inhibitor for Na+/K+ ATPase, we demonstrated that the enzymatic
activity as measured by µmols of Pi liberated/ mg of protein/ hour was
significantly reduced by ~25% in the hippocampi of aged, memory-deficient
APP+PS1 mice compared with non-transgenic littermates (Figure 2). These
values are consistent with those found 3 decades ago by Stefanovic et al. (1974).
Upon analysis of the cerebellum of these mice, we showed that the specific
enzyme activity in APP+PS1 transgenics remained equivalent to that in nontransgenic littermates; however the overall activity of Na+/K+ ATPase in this
region was only one fifth of that in the hippocampus (Figure 2).
The specificity of the Na+/K+ ATPase α subunit antibody used for
immunochemistry was determined by several means. Figure 3 demonstrates that
following a pre-incubation of the antibody with purified Na+/K+ ATPase protein,
staining with DAB+Ni2+ was dramatically reduced (Figure 3B) compared with
normal staining (Figure 3A; the bright red spots are amyloid plaques stained with
Congo red dye). Western blot analysis of the purified enzyme revealed two major
bands the largest corresponding to the 140kD whole Na+/K+ ATPase enzyme
consisting of both the α and β subunits and the smaller 110kD band
corresponding specifically to the dissociated α subunit only (Figure 3C). The
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Western banding pattern of mouse hippocampal homogenate (signified by the
“H” above the right lane) was virtually identical with that of the purified Na+/K+
ATPase (signified by the “P” above the left lane; Figure 3C). These data provided
sufficient evidence of the reliability of antibody specificity to continue with more
comprehensive anatomical analyses of the APP+PS1 cerebral Na+/K+ ATPase
distribution.
Immunohistochemical staining with DAB+Ni2+ of cerebral sections from
non-transgenic and APP+PS1 mice for the Na+/K+ ATPase α III subunit revealed
specific membrane-associated staining as evidenced by the high magnification
images in Figure 4 of CA3 pyramidal cell bodies (Figure 4A) and cell bodies of
the insular cortex (Figure 4B) with reticular staining in the neuropil. Lower power
images of the hippocampus in non-transgenic mice (Figure 4C) demonstrate an
absence of staining along the granular layer of the blades of the dentate gyrus.
Additionally, staining is less intense within the hilus and along the mossy fiber
projections to CA3, demonstrating a lower expression of this protein subunit in
the inner molecular layer of CA3, but not in the pyramidal layer (Figure 4A).
White matter lacked staining consistent with the need for high Na+/K+
ATPase activity only at the nodes of Ranvier in myelinated tracts. Cortical
staining (Figure 4D) revealed a fairly uniform pattern, with the exclusion of white
matter. There appears to be slightly less intense staining in cortical layers 1 and
2. The glaring difference in Na+/K+ ATPase staining between non-transgenic and
APP+PS1 forebrain areas is the absence of staining where amyloid plaques are
presumably present in the APP+PS1 mice (Figure 4E & F). Subsequent Congo
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red staining of these amyloid plaques confirmed that the absence of Na+/K+
ATPase staining was not only seen in the center of the plaque, but also in a
penumbral zone immediately surrounding the congophilic plaque, resulting in a
“halo” (Figure 4G & H). Higher power magnification clearly demonstrated the
lack of Na+/K+ ATPase staining surrounding the congophilic plaques (Figure 5A;
100x: Figure 5B; 400x).
These findings led us to postulate that the osmotic imbalance brought on
by an absence of Na+/K+ ATPase may result in the neuritic dystrophia
surrounding plaques, a pathological feature consistently seen in APP+PS1 mice.
We designed a dual immunostain utilizing immunohistochemical methods for
Na+/K+ ATPase and immunofluorescence methods for phosphorylated
neurofilament, a dystrophic neurite marker we evaluated earlier (Gordon et al.,
2002). Figure 5B is representative of our findings for Na+/K+ ATPase with Congo
red and Figure 5C is likewise representative of our findings for phosphorylated
neurofilament (dystrophic neurites) on the same plaque. Using this assay, we
were able to demonstrate that the dystrophic neurites were almost exclusively
present within the zone surrounding the congophilic plaque that lacked Na+/K+
ATPase staining, as represented by an overlay of the fluorescent neurites from
Figure 5C onto the bright field image of Na+/K+ ATPase and Congo red staining
from Figure 5B (Figure 5D).
Finally, to determine whether amyloid could inactivate Na+/K+ ATPase
activity, we measured the activity of purified cerebral Na+/K+ ATPase after
exposure to various concentrations of Aβ 1-42 peptide. Figure 6A shows that the
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amyloid preparation contained peptide forms corresponding to ~15, ~11, and
~4kD (right lane), when compared to the molecular weight standards in the left
lane. Figure 6B demonstrates that increasing concentrations of Aß dosedependently reduced Na+/K+ ATPase activity. There were significant reductions
in Na+/K+ ATPase activity at the lower concentrations of 112 and 225 µg/ml
compared to vehicle, but maximal reductions were at the highest concentration of
amyloid (450µg/ml).

DISCUSSION
Over the past 6 years, our group has characterized various aspects of the
APP+PS1 transgenic mice including their pathology, behavior, and gene
expression. With age, these mice progressively develop more amyloid plaques
surrounded by dystrophic neurites, activated microglia and astrocytes (Gordon et
al., 2002). With increasing amyloid burden, aged animals consistently develop
memory deficits in the radial arm water maze (RAWM; Holcomb et al.,
1999;Arendash et al., 2001;Gordon et al., 2001). We have also demonstrated
that several genes critical for synaptic plasticity and memory consolidation are
down regulated in these mice in regions accumulating amyloid (Dickey et al.,
2003) and the induction of a subset of immediate-early genes is impaired when
the transgenic mice are introduced to a novel environment (Dickey et al., 2004).
Here, we have shown that Na+/K+ ATPase has decreased mRNA
expression and enzyme activity in the amyloid containing hippocampus of
APP+PS1 transgenic mice. We have also demonstrated by immunohistology that
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Na+/K+ ATPase protein expression is reduced in the immediate vicinity of
congophilic plaques, a zone where dystrophic neurites are most prevalent,
suggesting that disrupted ionic homeostasis may contribute to their formation.
Additionally, high concentrations of Aβ 1-42 directly inhibit the activity of Na+/K+
ATPase. This suggests that in the area surrounding amyloid plaques, where the
local Aβ concentration is likely high, Na+/K+ ATPase activity is inhibited,
precipitating edema in neurites close to the plaques.
From previous gene expression studies, we found that the mRNA for the
Na+/K+ ATPase αIII subunit was significantly down-regulated in the hippocampi
of APP+PS1 mice compared to non-transgenic littermates and to the amyloidfree cerebella (Dickey et al., 2003). These reductions were also demonstrated in
human Alzheimer’s disease samples, consistent with data from previous
investigations (Chauhan et al., 1997; Dickey et al., 2003). Here, we have
replicated these findings in a separate cohort of aged APP+PS1 mice,
demonstrating a consistent deficiency (Figure 1). Two major advantages of the
qRT-PCR method are sensitivity and robustness, as discrete changes in
expression can be measured and sample size can be increased to allow for more
reliable statistical analyses, respectively. One problem is that current
conventional methods used to measure protein expression lack the same
sensitivity now available for RNA analyses, and therefore may not discern similar
phenomena at the protein level. Using Western blot analysis, we were able to
see slight differences in Na+/K+ ATPase protein level in transgenic mice;
however this approach lacked statistical significance and was less than
106

convincing to our eyes (a representative blot is shown in Figure 3C). Using a
sensitive colorimetric assay to measure activity of Na+/K+ ATPase developed by
Ellis et al. (2000), we were able to demonstrate that in the APP+PS1
hippocampus, the activity of ouabain-sensitive ATPase was significantly impaired
(Figure 2) while Na+/K+ ATPase activity in the amyloid-free cerebellum remained
unperturbed with respect to genotype. Cerebellar activity was substantially lower
than that seen in the non-transgenic hippocampal tissue, perhaps indicative of
the abundant white matter found in this region, where Na+/K+ ATPase would
predominantly be located at the nodes of Ranvier. These data demonstrate that
the function of Na+/K+ ATPase is perturbed in a brain region that contains high
overall concentrations of Aβ. Previous investigations have shown that in cultured
neurons, Na+/K+ ATPase activity can be blocked directly by various Aβ peptide
fragments (Mark et al., 1995) and other studies have shown that Na+/K+ ATPase
protein levels are decreased in AD tissue but not in normal aged tissue (Harik et
al., 1989;Liguri et al., 1990) But, this is the first time that reduced activity has
been demonstrated in homogenates from an animal model for amyloid deposition
indicating that in vitro effects of Aβ retain relevance in vivo. It remains uncertain if
the Aβ in the homogenate is directly inhibiting the enzyme in vitro, as the
homogenate is diluted 20 fold in the assay. However, even if this reduced activity
results from homogenate-derived Aβ inhibition in vitro, it clearly indicates there is
sufficient Aβ in vivo to block Na+/K+ ATPase activity.
We then immunostained APP+PS1 mouse sections for Na+/K+ ATPase to
better understand where the reductions in enzyme level were occurring. Initial
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examination of hippocampal staining revealed that in both the non-transgenic
and APP+PS1 mice, Na+/K+ ATPase staining was found to be membrane
specific (Figures 3A & B). Analysis of staining in both APP+PS1 and nontransgenic tissue also revealed reductions in Na+/K+ ATPase along the mossy
fiber pathway from dentate gyrus to CA3 and in the hilus and slight reductions in
layers 1 and 2 of the cortex (Figure 4A-F). Of particular interest, in areas where
congophilic plaque staining was apparent, Na+/K+ ATPase staining was absent,
and more specifically, there appeared to be no or little Na+/K+ ATPase staining
in a penumbral zone surrounding the plaques stained with Congo red (Figures
4E-H and 5A-B). From previous studies, we knew that dystrophic neurites could
be visualized in the APP+PS1 mice directly adjacent to congophilic amyloid
plaques (Gordon et al., 2002) and the finding of reduced Na+/K+ ATPase
staining in this same area suggests that dysregulation of the enzyme may in
some way be linked to the disruption of neurite integrity.
Subsequently, we stained sections for Na+/K+ ATPase and dystrophic
neurites together, along with amyloid plaques using Congo red. Because of the
ubiquitous distribution of both Na+/K+ ATPase and phosphorylated neurofilament
(used to label dystrophic neurites), we found empirically that staining the ATPase
immunohistochemically and the dystrophic neurites with a fluorescein labeled
secondary antibody was the most effective way to see both markers on the same
section along with the Congo red stained plaques. Imaging of these sections did
reveal that dystrophic neurites are in the circumferential area surrounding the
congophilic amyloid plaques where Na+/K+ ATPase staining is absent (Figure
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5D). One possible explanation for this would be that amyloid binding to the
Na+/K+ ATPase and inhibiting its activity would cause the neurites to begin
swelling, resulting in dysregulation of neuronal signaling. Another possible
mechanism for the reductions in Na+/K+ ATPase would be that interactions of
amyloid with surface proteins, such as integrins (Sabo et al., 1995;Goodwin et
al., 1997) and focal adhesion proteins (Williamson et al., 2002) lead to activated
signal transduction cascades that mediate tyrosine phosphorylation (Grace and
Busciglio, 2003) thereby promoting the removal of ATPase from the neuronal
membrane and its subsequent down-regulation. A recent study suggests that the
tyrosine kinase, Lyn, can phosphorylate Na+/K+ ATPase resulting in its removal
from the membrane (Bozulic et al., 2004). When taken together, these data
suggest that either direct inhibition of Na+/K+ ATPase by amyloid or its removal
due to amyloid-mediated activation of a signaling cascade, could result in the
formation of dystrophic neurites due to osmotic and ionic imbalances.
A final investigation analyzed the effects of amyloid peptide on the activity
of a purified cerebral preparation of active Na+/K+ ATPase. Amyloid has been
shown to bind various cell surface proteins (Mark et al., 1995;Dineley et al.,
2001;Verdier and Penke, 2004) and induce neuro-toxicity (Caughey and
Lansbury, 2003;Stine, Jr. et al., 2003;Gong et al., 2003). To determine the effect
of Aβ 1-42 on Na+/K+ ATPase activity, we pre-incubated purified Na+/K+
ATPase with varying concentrations of amyloid then colorimetrically measured its
activity. Although amyloid did suppress activity at 112 µg/ml (~10µM) and 225
µg/ml (~50µM), it was the highest concentration (450µg/ml or ~100µM) that
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precipitated the largest reduction in activity compared to vehicle, nearly rendering
it completely inactive (Figure 6B). This suggests that the Aβ 1-42 peptide can
directly binding to the Na+/K+ ATPase and affecting its activity. Mark et al.
suggests that the 25-35 amino acid region of the Aβ peptide induces oxidative
stress thereby impairing Na+/K+ ATPase activity (Mark et al., 1995), and the
findings presented herein strengthen the argument for the role of amyloid in
Na+/K+ ATPase dysregulation. Additionally, the presence of short 11 and 15 kD
polymers of amyloid in the DMSO/water preparation suggests that these might
be what is driving this reduced activity.
These data indicate that reduced activity in Na+/K+ ATPase may be
elicited by high concentrations of Aβ, which may then lead to local neuritic edema
and the appearance of dystrophic neurites in APP+PS1 mice. One area in the AD
brain that might harbor such a high concentration of Aβ as needed to suppress
the activity of Na+/K+ ATPase would be the microdomain near and immediately
around the plaques. This is the area demonstrated to have reduced
immunostaining for Na+/K+ ATPase. A previous study has suggested that when
Na+/K+ ATPase activity is specifically inhibited by ouabain, mice are unable to
consolidate new memories (Watts and Mark, 1971) and in addition cells exposed
to ouabain have reduced Na+/K+ ATPase αIII subunit mRNA expression (Huang
et al., 1997), confirming our findings that direct inhibition of Na+/K+ ATPase
activity can result in reduced mRNA expression, possibly through a yet
unidentified signaling cascade. These data suggest that drugs targeted at
activating Na+/K+ ATPase and maintaining ionic balance in these neurons may
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benefit Alzheimer’s patients by delaying both the onset of neuritic dystrophia and
memory dysfunction.
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FIGURE 1. Expression of Na+/K+ ATPase mRNA in APP+PS1 mice by qRTPCR.
This figure shows APP+PS1 transgenic mouse expression (n=7-8
APP+PS1, open bars) as a percentage of the average of non-transgenic
expression (n=7-8 Non-Tg, solid bars) for the Na+/K+ ATPase αIII subunit in the
hippocampus and the cerebellum. In 18 month old APP+PS1 mice, the amyloid
free cerebellum maintains expression equivalent to that of non-transgenic mice.
However, hippocampal expression of Na+/K+ ATPase is significantly decreased
in APP+PS1 mice compared with age matched littermates, indicating that the
amyloid contained within this region may be contributing to the decrease in
mRNA expression. The values represented in this figure are the mean + SEM.

*

indicates significant differences between APP+PS1 mice and non-transgenic
littermates (p < 0.05) when measured by one-way ANOVA. † indicates
differences (p < 0.05) in expression between hippocampus and cerebellum.
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FIGURE 2. Activity of the Na+/K+ ATPase enzyme in APP+PS1 mice
Activity of ouabain-sensitive ATPase was assayed colorimetrically in
APP+PS1 mice tissue (n = 8, open bars) and non-transgenic littermate tissue (n
= 8, solid bars) and is presented here as µmols of phosphate liberated by
Na+/K+ ATPase per mg of protein in one hour. Both amyloid-free cerebellar
tissue and amyloid containing hippocampal tissue were analyzed. There was no
decrease in APP+PS1 cerebellar Na+/K+ ATPase activity compared to nontransgenic mice. However, in the amyloid-containing hippocampus, there was a
significant decrease in the activity of the enzyme. Cerebellar activity was only
20% of that seen in non-transgenic hippocampus. The free-phosphate/molybdate
complex was measured at 660nm following a 30 minute incubation. Specific
activity was calculated as the difference between samples ± ouabain. A
phosphoric acid standard curve was used to calculate the molar concentration of
phosphate liberated by Na+/K+ ATPase/mg total protein/hour. The values
represented in this figure are the mean + SEM. * indicates significant differences
between APP+PS1 mice and non-transgenic littermates (p < 0.05) when
measured by one-way ANOVA.
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FIGURE 3. Verification of Na+/K+ ATPase αIII antibody specificity by
immunohistochemistry following pre-incubation with purified protein and Western
blotting.
Horizontal sections were immunostained for Na+/K+ ATPase αIII with
(Panel B) and without (Panel A) pre-incubation with 70 µunits of purified enzyme
followed by DAB with nickel intensification and Congo red staining. The preincubation significantly decreased staining, confirming antibody specificity. Panel
C is a representative western blot for Na+/K+ ATPase αIII using both purified
Na+/K+ ATPase (“P” lane) and hippocampal homogenate (“H” lane). Both lanes
have two predominant bands at 140 and 110kD, corresponding to the whole
enzyme and the α subunit, respectively, as indicated by the arrows. Scale bar for
panels A and B = 50µm.
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FIGURE 4. Hippocampal and cortical immunohistochemistry for Na+/K+ ATPase
in APP+PS1 mice and non-transgenic littermates.
Twenty five µm horizontal hippocampal and cortical sections were
immunostained for Na+/K+ ATPase αIII followed by DAB with Ni2+
intensification. Left panels are hippocampus, right panels are cortical sections.
High power magnification (Panels A & B; Scale bar = 8.33µm) revealed
membrane-specific staining of neuronal cell bodies for Na+/K+ ATPase in the
insular cortex (Panel B) and CA3 of the hippocampus with less intense staining
of the mossy fiber pathway (Panel A). Hippocampal staining of non-transgenic
mice showed a ubiquitous distribution of Na+/K+ ATPase throughout the gray
matter, while less staining was apparent along the pyramidal layer of Ammon’s
horn, the hilus and the granular layer of the dentate gyrus (Panel C). Cortical
staining was also substantial with slight faintness in layers 1 and 2 (Panel D).
White matter in both structures remained unstained. A similar staining pattern
was observed in the APP+PS1 mice with the exception of large non-stained
holes in the gray matter, presumably where amyloid plaques are located (Panels
E & F). Immunostaining followed by Congo red histochemistry confirmed that the
Na+/K+ ATPase staining was absent not only immediately where plaques are
located, but also in a zone surrounding the plaque (Panels G & H). Scale bar for
panels C-H = 120µm.
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FIGURE 5. Dual Immunostaining of Na+/K+ ATPase αIII and dystrophic neurites.
Horizontal sections were immunostained for Na+/K+ ATPase using DAB
with nickel intensification followed by Congo red staining for Aβ plaques after
which a discernable circumferential void in ATPase staining surrounding the
plaque was observed (Panel A 100x magnification; Panel B 400x magnification).
Immunofluorescent staining of dystrophic neurites using the anti-phosphorylated
neurofilament antibody SMI-312 followed by Congo red staining demonstrate a
close relationship between amyloid plaques and dystrophic neurites (Panel C;
Congo red yellow fluorescence was digitally suppressed to more clearly reveal
the green-stained neurites). This double immunostaining procedure is shown as
a digital overlay of the fluorescein-labeled dystrophic neurite image onto the
bright field peroxidase-labeled Na+/K+ ATPase + Congo red image in panel D
which demonstrates that dystrophic neurites are present predominantly in the
zone devoid of Na+/K+ ATPase staining surrounding the congophilic plaques (C).
Scale bar for Panel A = 50µm; scale bar for Panels B-D = 16.67µm.
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FIGURE 6. Amyloid-beta 1-42 inhibits Na+/K+ ATPase activity at high
concentrations.
SDS-PAGE analysis followed by comassie blue staining revealed; 15 kD
tetramers, 11kD trimers and 4kD monomers of Aß were present in the
DMSO/water suspension (Panel A; left). Purified cerebral Na+/K+ ATPase was
pre-incubated with three concentrations of the Aβ 1-42 suspension. Panel B
describes the effects of Aβ on Na+/K+ ATPase activity as a percentage of the
vehicle. The activity measured in the presence of each concentration of Aβ 1-42
is indicated by the diamond symbol connected by a line. These findings
demonstrate significant effects of all three concentrations of Aβ on activity, with
75% ablation of activity at the highest concentration of 450µg/ml. The assay was
measured spectrophotometrically at 660nm following a 2 hour pre-incubation with
the Aβ preparations and a subsequent 30 minute reaction time. Values are
presented here as a percentage of the activity of purified Na+/K+ ATPase
incubated vehicle. The effect of the 2 hour pre-incubation on activity is negligible
and indicated by the 0 µg/ml concentration. A phosphoric acid standard curve
was used to calculate the molar concentration of phosphate liberated by Na+/K+
ATPase. The values represented in this figure are the mean + SEM. * (p < 0.05)
and *** (p < 0.001) indicates significant differences between vehicle + Aβ and
vehicle alone when measured by one-way ANOVA.
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CONCLUSIONS

Since the creation of the first transgenic mouse in 1982 by Palmiter, Chen
and Brinster (Palmiter et al., 1982) and the subsequent use of embryonic stem
cells to knockout genes in mice (Bradley et al., 1984), the ability to alter
molecular expression has lead to many ground breaking discoveries in medical
sciences. Through the use of transgenic and knockout mice, scientists have been
able to identify the function of many human genes as well as the causes for a
host of diseases plaguing mankind. Over the past 2 decades, many
manipulations of these two systems have been reported allowing for expression
of multiple genes in a single animal or the ability to induce these systems with a
dietary supplement (Mortensen, 1993;Saam and Gordon, 1999;Shockett et al.,
1995;Bockamp et al., 2002).
Alzheimer’s disease (AD) relies heavily on these technologies as the
pathology associated with AD is an effect of the gradual accumulation of
abnormal proteins in the brains of patients that eventually leads to the clinical
manifestation of severe cognitive damage. Only a model that can duplicate this
slow deleterious progression of pathology can be used to develop treatments for
AD. Pathological indicators for AD include forebrain amyloid deposition resulting
in extra-cellular plaques of β-pleated sheets and intracellular accumulation of
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hyperphosphorylated tau filaments. A proper model for AD would also realize
severe neuron loss and glial activation, as well as dystrophic neurites. But
perhaps the most important feature for a model of AD to have is the inability to
consolidate newly acquired information into lasting memories.
Mutant forms of the human APP and PS1 genes, which have been linked
to a more aggressive form of AD pathological progression, were used to
generate transgenic mice. Singly transgenic APP mice were demonstrated to
develop amyloid pathology and glial activation (Hsiao et al., 1996), while singly
transgenic PS1 mice lacked any significant plaque pathology (Duff et al., 1996);
however, neither model developed consistent memory deficits. These mice were
then crossed to breed viable doubly transgenic progeny (Holcomb et al., 1998).
The over-expression of the two transgenes led to an enhanced forebrain amyloid
pathology and glial activation. In addition, these mice developed cognitive deficits
that were correlated with amyloid deposition (Holcomb et al., 1999). Since that
time, the APP+PS1 doubly transgenic mouse has provided a good model for
therapeutic development against amyloid-associated dementias. Over the past 6
years, our group has thoroughly characterized the pathology and behavior of
these mice, and more recently we have begun to analyze the molecular changes
in the APP+PS1 brain that may present other therapeutic targets for future
benefit to AD sufferers.
Here we present evidence describing altered gene expression in the
APP+PS1 mice compared to non-transgenic littermates. Initial microarray
analysis revealed that only 5 genes were down-regulated in the amyloid129

containing forebrain of the APP+PS1 mice, whereas the amyloid-free areas
lacked any significant down-regulation; Dickey et al., 2003). These 5 genes have
been linked to synaptic plasticity and memory function, demonstrating their
potentially critical role in the memory deficits of APP+PS1 mice. Additionally,
expression of genes associated with inflammation and the acute phase reaction
were up-regulated selectively in the amyloid-containing regions (Paper I; Table 2)
while other genes, such as APP, were upregulated in both amyloid-containing
and amyloid free regions compared to non-transgenic mice due to transgene
over-expression (Paper I; Table 3).
Using quantitative real time PCR (qRT-PCR), we were able to confirm
most of the microarray results and add several others genes in the same
categories as those found by the microarray (Paper I; Figure 1). One important
feature of these data was the finding that multiple genes also associated with
synaptic plasticity and mnemonic processes, such as Gap43, Rheb and several
synaptic vesicle related markers, were not down-regulated in the amyloidcontaining region of APP+PS1 mice, suggesting that specific mechanisms are
being interfered with in the APP+PS1 forebrain in response to the presence of
amyloid. As of this writing, we have found a total of 11 genes that are downregulated in the amyloid containing hippocampi of 17-18 month old APP+PS1
mice, and each of these is involved in synaptic plasticity to some degree. Of
these 11 genes, 6 belong to the inducible immediate-early gene category while
the other 5 are more stably expressed, but are still linked to lasting changes in
synaptic morphology and function (Table 1). LTP- or LTD-induced synaptic
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plasticity and the resultant gene expression have been shown to be essential for
the long-term storage of memories in the cortex (for review see Steward, 2002
and Lynch, 2004). These findings emphasize that the amyloid-associated
disruption of synaptic plasticity-related mRNA expression in the APP+PS1 mice
may be responsible for their inability to consolidate memories.
We also analyzed expression of these genes in both AD and nondiseased human tissue which revealed that the amyloid-containing region had
decreased expression of all mRNAs analyzed, while the amyloid-free tissue
maintained normal expression (Paper I; Figure 2). We attributed this non-specific
loss of all mRNAs to the neurodegeneration seen with AD which is absent in the
APP+PS1 mice. Together, these findings demonstrate that in amyloid-containing
brain regions of memory-deficient APP+PS1 mice, there is a selective reduction
of mRNAs associated with learning and memory, and that this impaired
expression may be contributing to their memory dysfunction.
To further analyze the dynamics of these reductions in mRNA expression,
we examined tissue from APP+PS1 mice at three time points. Due to the
expense associated with qRT-PCR, we chose three representative genes from
both the IEG (Arc, Zif268 and Nur77) and other plasticity-related (CaMKIIα,
AMPA1 and Na+/K+ ATPase αIII) categories, as well as two non-changing genes
(synaptophysin and Gap43). Mice at 2 months of age lacked any reductions in
expression of the genes we analyzed, a significant finding because it ensured
that the reductions seen in the older mice were not due simply to APP and PS1
over-expression, but rather the pathological accumulation of amyloid elicited by
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their expression (Paper II; Figure 1). Another interesting outcome of this time
course analysis was that at 6 months, an age when fibrillar amyloid plaques are
just beginning to appear, the IEGs were already significantly down-regulated,
while the other plasticity-related genes had not yet demonstrated significant
reductions (Paper II; Figure 1); however, by 18-months, when memory deficits
and high amyloid burden are consistently detectable (Gordon et al., 2002;Gordon
et al., 2001), both sets of genes were down-regulated (Paper II; Figure 1),
suggesting that amyloid must be present at a sufficiently high concentration to
block expression of both IEG and other plasticity-related mRNAs to initiate
cognitive decline.
Additional evidence for the enhanced sensitivity of IEG expression to
lower amounts of Aβ was found when we analyzed APP and PS1 singly
transgenic mice. The expression of IEGs was significantly decreased in APP only
mice whereas the other plasticity related genes were not down-regulated, a
similar phenomenon to that seen in the 6-month old APP+PS1 mice (Paper II;
Figure 2). Interestingly, 18-month old APP singly transgenic mice and 6-month
old doubly transgenic mice have a very similar amyloid load and both lack
detectable memory deficits. The amyloid-free PS1 singly transgenic mice did not
exhibit any significant loss in expression of the genes we analyzed (Paper II;
Figure 2). This emphasizes the significance of the massive amyloid burden
found in aged APP+PS1 mice and the necessity for the down-regulation of not
just the IEGs, but also the other plasticity related genes for memory deficits to
occur.
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Previously, we described that gene expression in the amyloid-free
cerebellum remained consistent with non-transgenic littermates, demonstrating
specificity for the down-regulated genes (Paper I; Figure 1). Subsequent
expression analyses of the posterior cortex from 18-month old APP+PS1 mice, a
region with a less concentrated amount of amyloid, and the caudate nucleus
(striatum), which lacks any formation of plaques but has a high level of diffuse
amyloid load, revealed once again that IEG expression is dysregulated by the
presence of lower plaque load than the other plasticity-related genes. IEG
expression was inhibited in all three regions analyzed, while the other plasticityrelated genes were only down-regulated in the hippocampus (Paper II; Figure 3).
The down-regulation of IEG expression in the striatum is of particular interest due
to the lack of plaque formation, but high soluble Aβ load. This perhaps provides
the greatest evidence that amyloid itself is facilitating this disruption in some way.
Together, the time course, genotype and anatomical analyses of
expression provide thorough evidence that amyloid is causing the downregulation of IEG expression, but it is only when plaque formation is dramatically
increased that the other plasticity-related genes are down-regulated and
detectable memory function is disrupted. One possible reason for the apparent
necessity of both sets of genes to be down-regulated for memory deficits to occur
could be due to the lack of sensitivity of current behavioral trials. It could be that
memory is just beginning to fail at the time when IEG expression is first downregulated. Recent reports have described impaired cognitive function when IEG
expression is dramatically knocked down or ablated entirely (Guzowski et al.,
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2000;Bozon et al., 2003), but current methods to detect discreet changes
associated with marginally down-regulated expression, as is the case of the
APP+PS1 mice, may not yet be sufficiently discriminating.
The issue of the molecular mechanisms behind the amyloid-associated
memory loss presents a unique challenge because of the slow development of
pathology. Initially, we decided to address the issue of whether the induction of
IEG expression or the low-level basal expression was impaired in the APP+PS1
mice. This was critical because these genes are massively up-regulated following
transcriptional induction, at which point they are capable of eliciting their most
robust effects. Following induction, IEG expression transiently returns to near
undetectable levels within 24 hours. Previously, to control for exactly this
possibility, each mouse was transported from the vivarium to the laboratory and
set aside for 30 minutes, assuming that the environmental change would be
sufficient to induce IEG expression.
To test if induction was in fact being sufficiently facilitated by a simple
environmental change, we introduced one of two cohorts of mice (each cohort
consisted of 7-8 APP+PS1 mice and 7-8 non-transgenic littermates) to a novel
environment for 5 minutes and then returned them to a new cage for 30 minutes
prior to sacrifice. The other cohort was swiftly removed from their home cage and
immediately anesthetized. We designated the former as “induced” and the latter
as “basal”. Quantitative RT-PCR of the hippocampi of these mice revealed that
both APP+PS1 mice and non-transgenic littermates experienced significant
induction of the IEGs Arc, Nur77 and Zif268, however the induction of Arc and
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Nur77 in the APP+PS1 was significantly impaired compared to the nontransgenic mice (Paper II; Figure 4). Additionally, the expression of the basal
animals was the same for both transgenic and non-transgenic. This was an
essential piece of evidence, as it ensured that our previous data were measuring
functional expression of the IEGs. Zif268 induction was not significantly impaired
in this paradigm, a finding not unexpected as the half-life of Zif268 message is
longer than most IEGs, making it more difficult to analyze based on a single
behavioral event. But, similar to the other 2 genes, the basal expression
remained the same for both APP+PS1 and non-transgenic mice, further
validating the method of induction used in our previous studies.
There are several possible arguments as to why IEG expression is
decreased, including that amyloid may be binding very specifically to a cell
surface protein, inhibiting a signaling cascade essential for IEG activation. The
MAPK signaling cascade, specifically ERK, and CREB have both been
implicated in the transcriptional initiation of IEG expression (Sgambato et al.,
1998;Ying et al., 2002;Murphy et al., 2004). Particularly, activation of the NMDA
receptor has been shown to elicit expression of several IEGs, and this activation
requires the MAPK cascade (Walker and Carlock, 1993;Cammarota et al., 2000;
Sato et al., 2001). Amyloid and its various peptide fragments have been shown to
inhibit LTP and facilitate LTD in an NMDA receptor-dependent manner (Kim et
al., 2001). Therefore it is possible that amyloid is disrupting LTP via a specific
interaction with the NMDAR, which in turn prevents sufficient stimulation to
induce IEG expression. To further postulate, the reduced expression of the NR2B
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subunit in the APP+PS1 mice at a point when amyloid-burden is high may
suggest a negative feedback mechanism for the LTP system, in which perpetual
ligand binding of the NMDAR eventually results in its decreased mRNA
expression, similar to that seen with thyroid hormone receptor systems
(Guissouma et al., 2000). However, these putative explanations are in conflict
with the fact that the clinical use of low concentrations of the NMDAR antagonist,
memantine (for review see Danysz and Parsons, 2003) is beneficial for the
treatment of AD. Perhaps the clinical manifestation of AD is due in part to an
over-activation of brain circuitry, in essence drowning out the fine-tuned signaling
required for mnemonic function, a situation that may be attenuated by mild
inhibition of the NMDAR.
Another possible mechanism that may be altered due to
agonist/antagonist relationships of amyloid with various receptors, is calcium
signaling pathways. Evidence for amyloid binding to both nicotinic and
muscarinic cholinergic receptors has been reported (Dineley et al., 2002;Kelly et
al., 1996), both of which are involved in Ca2+ signaling, either by increasing its
conductance into the cell or by releasing intracellular stores, respectively. We
have demonstrated that the expression of the catalytic subunit of
Ca2+/calmodulin-dependent kinase (CaMKIIα) is down-regulated in APP+PS1
transgenic mice, and has significantly reduced expression in the presence of
lower levels of amyloid, unlike the other plasticity-related genes, AMPA1 and
Na+/K+ ATPase (Paper II; Figures 1 and 3), although not to the same extent as
the IEGs. This suggests that calcium signaling may be disrupted in the presence
136

of low amyloid burden and this may be precipitating the decrease in IEG
expression. As calcium signals are shorter-lived than other cascade messengers,
they present good candidates for initiators of the transcription of the extremely
transient IEGs (Greenberg et al., 1992;van Haasteren et al., 1999). Conversely,
intracellular calcium release was found to be facilitated by an AD-linked mutated
form of PS1 (Stutzmann et al., 2004). As these findings suggested, AD-linked
mutations in PS1 may not only result in the over-production of Aß ,but also of the
APP intracellular domain (AICD), which is the fragment thought to stimulate the
activation of IP3 receptors on the endoplasmic reticulum (Leissring et al., 2002).
This increased intracellular calcium release was demonstrated to activate Ca2+sensitive K+ channels on the cell surface, resulting in a hyperpolarization. This
may explain another mechanism by which calcium is impeding normal neuronal
function and decreasing signal transmission.
In addition to amyloid pathology, APP+PS1 mice develop chronic focal
inflammation surrounding fibrillar plaques. This includes activation of microglia
and astrocytes (Gordon et al., 2002), which can elicit cytokine release, acute
phase reactants and free radical production. APP production is even thought to
be promoted by interleukin 1 demonstrating the role that cytokines may have on
disease progression (Blume and Vitek, 1989). Transcriptional regulation of IEG
expression by cytokines has been well established (Emch et al., 2001;Konsman
et al., 2000) and, while this is a possible mechanism by which IEG expression is
being inhibited, it is unlikely because IEG expression is significantly decreased
by 6 months in the APP+PS1 mice, a point at which amyloid is accumulating with
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little inflammatory response (Gordon et al., 2002;Apelt and Schliebs, 2001). In
addition, most reported cytokine effects on IEG expression have shown that
increased cytokine production elicits an increase in IEG expression, not a
decrease (Jenab and Quinones-Jenab, 2002;Simi et al., 2002;Heinrich et al.,
2003).
Besides the elegant possibilities discussed above, there is perhaps a
more rudimentary explanation for impaired IEG induction; that the neurons simply
cannot conduct adequate electrical impulses any longer. One of the plasticityrelated genes with consistently down-regulated mRNA expression in amyloidcontaining APP+PS1 mice tissue was Na+/K+ ATPase αIII (Paper I; Figure 1:
Paper II; Figures 1, 2 and 3: Paper III; Figure 1). Na+/K+ ATPase is more than a
plasticity-related gene in that it consumes nearly 40% of the ATP in brain tissue
and maintains the membrane potential throughout the parenchyma, emphasizing
its critical role in every function of the brain. Without Na+/K+ ATPase, neurons
would not be able to maintain membrane potentials resulting in the loss of their
ability to conduct electrical impulses and subsequently store information (Watts
and Mark, 1971). To ascertain whether this enzyme was malfunctioning in the
APP+PS1 mice, we analyzed the activity of oubain-sensitive ATPase in cerebral
tissue of memory-deficient APP+PS1 mice compared with non-transgenic
littermates. We found that there was significantly impaired Na+/K+ ATPase
activity in the hippocampi of APP+PS1 mice, but not in the cerebella (Paper III;
Figure 2). These findings suggested that the reduced activity is precipitated by
the presence of amyloid.
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Subsequent histological analyses of APP+PS1 cerebral sections showed
that although Na+/K+ ATPase stained the sections ubiquitously, the area
immediately surrounding Congo red stained plaques lacked Na+/K+ ATPase
almost entirely (Paper III; Figures 4 and 5). The absence of Na+/K+ ATPase from
this circumferential zone around plaques would disrupt the membrane potential
of any cellular components in that area, which is the exact area where dystrophic
neurites are normally seen. Triple staining of Na+/K+ ATPase, dystrophic
neurites and congophilic plaques revealed that the dystrophic neurites were in
fact within the Na+/K+ ATPase-free zone surrounding the fibrillar plaques (Paper
III; Figure 5). Soluble Aß was subsequently prepared in accordance with Stein et
al. (2002) and incubated with purified cerebral Na+/K+ ATPase to assess
whether or not amyloid could directly inhibit enzyme activity. Interestingly, high
concentrations of this Aβ preparation did dramatically inhibit activity (Paper III;
Figure 6), suggesting that in a local area of high amyloid concentration, such as
the area immediately surrounding an amyloid plaque, Aβ may bind to Na+/K+
ATPase leading to its inactivation and subsequent removal from the membrane.
It has also been reported that specific inhibition of Na+/K+ ATPase leads to
reduced mRNA expression of the αIII subunit (Huang et al., 1997), providing an
explanation as to why the mRNA expression is also down-regulated.
One of the hallmark pathological features of the APP+PS1 mouse is the
presence of dystrophic neurites without actual synaptic or neuronal loss (Gordon
et al., 2002;Jantzen et al. In Preparation). These dystrophic neurites are
synapses that are presumably no longer functioning properly and appear swollen
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and disjointed. The exact mechanism by which these neurites form is largely
unknown, although it has been postulated that amyloid interacts with various
surface proteins which in turn stimulate signaling cascades and consequently
lead to the accumulation of hyper-phosphorylated neurofilament and the
formation of dystrophic neurites (Grace and Busciglio, 2003). Here we have
presented evidence that in models of amyloid deposition, the AD-like dystrophia
may occur due to amyloid directly inhibiting Na+/K+ ATPase activity, resulting in
ionic imbalance and the resultant osmotic swelling (Cooke, 1978). Presumably,
synapses that have become dystrophic are no longer able to conduct action
potentials to the post-synapse. Possibly, neurons in an amyloid-induced
dystrophic state increase expression of several anti-apoptotic genes (Chaudhury
et al., 2003;Tortosa et al., 1998) leading to the down-regulated expression of
genes involved in neurotransmitter release. This would suggest that neuronal
function turns from the collective parenchymal purpose of information transfer to
the more immediate necessity of survival. Another possibility may be that
dendritic swelling brought on by osmotic imbalance via Na+/K+ ATPase inhibition
could actually hamper post-synaptic conduction simply by increasing the area
(intracellular volume) that the current has to traverse. This may impede the ability
of gray matter to propagate electrical signals along the entire length of the
dendritic spine, preventing sufficient depolarization at the axon hillock for
subsequent synaptic transmissions.
Based on the results described here, it is feasible that the blockade of
Na+/K+ ATPase activity by amyloid results in the dysregulation of the neuronal
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membrane potential which in turn leads to the appearance of swollen,
dysfunctional neurites. The inability of these neurons then to conduct action
potentials and elicit specific stimulatory signals like LTP may result in the
formation of improper synaptic connections, damaged plasticity, and a general
failure to consolidate information received in the form of discrete patterns of
electrical frequencies into lasting memories. Late phase LTP, which has been
linked to long-term memory consolidation (Nadel and Moscovitch, 1998;Abraham
et al., 2002), is reported to be a critical component of molecular plasticity events,
namely that late-phase LTP blockade results in inhibition of IEG expression
(Richardson et al., 1992;Abraham et al., 1993;Barnes et al., 1994). The amyloidinduced neuritic dystrophia described above may be disrupting the connectivity of
circuits critical for memory formation, leading to the inability of neurons to
conduct late-phase LTP. This may prevent the expression of IEGs and the
subsequent effects on necessary persistent plasticity changes elicited by their
induction.
Circuits essential for learned behavior have been well established and
generally initiate in the hippocampus, with projections to the entorhinal cortex
and parietal cortex (Izquierdo and Medina, 1997). After repeated training, only
the parietal cortex is required for recall of this specific task, while the
hippocampus and entorhinal cortex are no longer involved. It has also been
established that LTP-induced protein expression is required for these circuitous
network changes to occur and be maintained (Guzowski et al., 2000;Frankland et
al., 2001). This suggests that disruption of the ability of these particular circuits to
141

relay electrical signals would result in the inability to form lasting connections
essential for memory formation, as experienced by Alzheimer’s diseased patients
and amyloid mouse models. Additionally, it may not be the sheer volume of
forebrain amyloid that is driving these memory deficits, but rather where
specifically the amyloid is depositing, possibly explaining why behavioral deficits
do not always correlate with IEG expression or amyloid load (Holcomb et al.,
1999). In other words, as amyloid load increases, the chances of a plaque
depositing in the middle of a long-term memory circuit are significantly increased.
Therefore, the critical issue in amyloid-associated dementia may not be how
much amyloid is present, but rather where the amyloid is deposited and what
neuronal networks are being disrupted.
Here we have presented evidence that amyloid plaques locally inhibiting
Na+/K+ ATPase activity in APP+PS1 mice, may result in disruption of electrical
signaling in brain regions essential for the establishment of lasting forms of
memory by promoting neuritic dystrophia. This disruption would likely result in
reduced IEG expression due to the resultant insufficiency of electrical signaling.
The reduced IEG expression at 6 months in APP+PS1 mice (Paper II; Figure 1)
is possibly a result of inactivated Na+/K+ ATPase, however sufficient disruption
of the circuits essential for memory consolidation are yet to be realized as
amyloid burden is still relatively low. Only when plaque load increases are
networks adequately impaired to cause detectable memory deficits. These
findings present several candidates for pharmacological intervention in amyloidassociated dementia, including several IEGs as well as other plasticity-related
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genes (e.g. CaMKIIα and AMPA1). The exact mechanisms by which these genes
are dysregulated and their link to memory formation have yet to be understood.
However, we have demonstrated a close relationship between amyloid and
impaired expression of several memory-associated genes, as well as a direct
inhibition of Na+/K+ ATPase activity by amyloid, suggesting that therapeutic
intervention targeting the well characterized enzyme may be warranted.
Maintaining the ionic balance of critical mnemonic circuits through the
administration of Na+/K+ ATPase agonists like phenytoin, may prove highly
therapeutic to AD sufferers, possibly delaying the emergence of cognitive
symptoms for several years and reducing medical and long-term care costs by
billions of dollars.
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TABLE 1. Genes that are selectively and significantly down-regulated in
the amyloid-containing hippocampi of APP+PS1 mice (qRT-PCR data).

Category

Immediate-Early
Genes

Other PlasticityRelated Genes

Gene Name

NCBI Genbank
Accession #

qRT-PCR Data
Percentage of
nontransgenic
mean ± SEM

Arc (Arg3.1)

NM_018790

48+10

Zif268 (Egr-1)

M20157

45+ 8

Nur77 (Nurr1)

J04113

60+ 8

Homer1a (Vesl-1)

AF093257

60+ 7

Narp (Nptx2)

AF049124

62+ 8

β-A Activin

D83213

69+ 7

CaMKIIα

NM_009792

65+ 6

AMPA1(GluR 1)

NM_008165

70+10

NR2B

NM_008171

82+ 5

Na+/K+ ATPase

BC020177

57+ 4

PSD-95

D50621

82+ 5
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APPENDIX A: QUANTITATIVE REAL TIME PCR (QRT-PCR) PROTOCOL

Primer Design.
1. Using the gene of interest (GOI), find the accession number that
corresponds to the proper species with cDNA or mRNA at the end of the
name, and copy and paste the sequence into a word processor.
2. Delete about 50% of the 3’ end of this sequence, as eukaryotic RNA
degrades from that end.
3. Using the internet based primer design program called Primer3
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi), paste
the shortened sequence into the proper field.
4. Set the specification of the amplicon size to be within 75-200bps, optimally
@ 100bp. Also use the rodent mispriming library available with the
program.
5. Specify the Tm (annealing temperature) to range be between 60˚C and
65˚C.
6. Also set the GC content between 50 and 60%. The primers should have
~55% GC content and their Tm should be within 1-2˚C of each other.
7. Select the number to return field and type in 20. This will return 20
possible pairs rather than the standard 5 pairs the program uses for
default.
8. The program returns possible primer pairs in different regions of the
sequence, with the best option listed first.
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9. Select a primer set in which both have similar properties, particularly the
same GC content as this determines Tm and check their self-hybridization
properties on the Operon website in their “Oligo Toolkit”.
10. Any pair with more than 4 nucleotides having primer-dimer potential are
not used.
11. The Operon website is also where the Tm is derived that should be use in
the actual PCR reaction.
12. Then search Genbank for sequence homology of the F primer. If a match
of 15 or more nucleotides are found in the same species, check the
reverse complimentary sequence of the R primer in a similar manner. If
matches of 15 or greater are found for both, do not use the primers and
select a new set from the Primer 3 output.
13. After finding no evidence of other potential targets, primers are ordered
from IDT.

RNA Extraction.
1. Frozen tissue dissections are homogenized using a tissue-mizer
instrument for 30 seconds in 700ul of RLT buffer plus β-mercaptoethanol
(see Qiagen RNeasy protocol). The rotor-stator is rinsed with clean water
and 70% ethanol between samples and dried with a Kim-Wipe.
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2. Qiagen RNeasy mini-spin columns are used to purify RNA according to
Qiagen’s protocol. Additionally, samples were treated with RNase-free
DNase from Qiagen.
3. 20mg of tissue/column is the ratio used, yielding approximately 16ug total
RNA/20mg of brain tissue.
4. RNA was eluted in water and total RNA concentration was determined by
Ribogreen Assay (Molecular Probes) using a standard curve (See
Molecular Probes Protocol).
5. The concentration is adjusted to 50ng/ul and RNA quality is checked by a
1% agarose gel with ethidium bromide.

Reverse Transcription.
1. The reverse transcription (rev txn) is performed using 8 mass quantities of
total RNA diluted down from a 50ng/ul standard intra-assay sample pool.
This should cover 3 logs (50, 20, 10, 5, 2, 1, 0.5, 0.2ng/ul). For single
samples, make a 1:10 dilution of each with water to yield 5ng/ul.
2. Plan ahead about how many genes you want to analyze and the number
of samples you have. 24 samples allows for a single PCR plate to be used
per gene with triplicates of each plus the standards. More than 24 samples
requires that two plates be used for each gene and therefore duplicate
standards on each of these plates must be
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accounted for (quadruplicates in total) to control for plate-to-plate
variation.
3. Additionally, pipetting is critical for real time PCR, so using 8-strip PCR
tubes, mini-master mixes are made for each sample and standard to draw
replicates (triplicates, quadruplicates, etc.) from. Therefore, a slight excess
is required in each tube, making enough for 3.5 replicates or 4.5
replicates. This adds to the total number of cDNA needed from the
beginning.
4. Therefore, each gene will require at least 7ul (for 3.5 triplicates) of cDNA
per sample and each reverse transcription reaction is 20ul, so nearly 3
genes can be analyzed per reverse transcription reaction.
e.g. 9 GOIs * 7ul = 63ul. Therefore 3.5 reverse transcription reactions
(70ul) would be needed for each sample and standard to allow for
complete analysis of all 9 GOIs.
5. The following equation will yield the total number of reverse transcription
reactions needed:
# of samples (24) + # of standards (8) * number of rev txn reactions (3.5)
= total # of rev txn reactions (112
excess).
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6. Make a master mix for the total # of rev txn reactions using the following
components (volumes are based on a single rev txn reaction rather than
the total needed for the 118 reactions mentioned above)
a. 0.5ul of 500ng/ul Oligo d(T) 15-21
b. 0.5ul of 500ng/ul Random Hexamers
c. 4ul of 5x 1st Strand Buffer
d. 4ul of 25mM MgCl
e. 2ul of DTT
f. 1ul of dNTPs
g. 6ul of 5M Betaine (provides thermostabilization to RT enzyme and
enhancing denaturation)
h. 0.87ul RNAse free water (vortex here prior to addition of enzyme)
i. 0.13 200U/ul MMLV reverse transcriptase
7. Mix by pipetting, and aliquot required volume minus RNA (19ul * number
of need RT reactions) into a 96-well hard shell PCR plate
8. Transfer 1ul * the number of needed RT reactions of 5ng/ul sample RNA
or varied concentration standard RNA into corresponding tubes
9. Mix by pipetting, cover with film (MJ Research Microseal A) and place into
the thermal cycler.
10. Create a program for 10 minutes at 25°C, 30 minutes at 42°C, 30 minutes
at 60°C and 5 minutes at 95°C to kill the enzyme and stop the reaction.
11. After this is finished, spin gently and use as cDNA.
165

APPENDIX A: (CONTINUED)
Primer Optimization.
1. This step is important, particularly for SYBR green reactions that lack the
specificity of Taqman probes and require a melt curve analysis.
2. The qRT-PCR reactions can be run at 50ul or 25ul/well, but with 25ul,
extra care must be given to sealing the plate because evaporation can
occur on the edge wells.
3. Primers for GOI are diluted to 100uM stocks in water and then further
diluted 1:20 to 5uM in water.
4. The cDNA from the rev txn reactions is not cleaned up or purified in any
way and added straight to the PCR reactions. Any species specific cDNA
pool at 50ng/ul can be used for the primer opt to spare that which was just
made.
5. Using the primer design parameters mentioned above, the final in-well
concentration of F and R primers is usually 300nM each. To save
reagents, do an initial screening at these concentrations and look at the
melt curve analysis. Therefore the reaction mix for a single PCR reaction
of a single sample is as follows (multiply by the # of PCR reactions
needed, usually 3.5 per samples):
a. 12.5ul of 2x SYBR green master mix
b. 7.5ul water
c. 1.5ul F primer
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d. 1.5ul R primer
e. 2ul cDNA
6. Aliquot enough mix for 3.5 reactions (replicates) into 8 strip PCR tubes
and then mix 10 times with cDNA . Aliquot 25ul from these 8-strip PCR
tubes to corresponding wells of a 96-well hard skirted PCR plate.
a. Be very careful when making the replicates during aliquoting that
excess reaction does not get into the wells from one replicate to the
other (the viscosity of the mix due to the presence of Tris/DMSO
may cause the liquid to cling to the outside of the tip). Be sure to
use filter tips for everything and mix the master mix very well before
aliquoting into the plate.
b. The plates (MJ Research) used are specially designed as well as
the film (MJ Research Microseal B) that covers them to be optically
clear.
7. Plates are then spun at a low speed and then can be stored at 4˚C for 24
hours.
8. The PCR is as follows:
a. 1 cycle of 95˚C for 5 minutes (this activates the hot start Taq)
b. 40 cycles of:
i. 95˚C for 15 seconds
ii. Suggested annealing temperature from Operon (58-65˚C) for
1 minute
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c. Then the melt curve program runs which starts at 55˚C and
increases 0.5˚C every 10 seconds until 100˚C. It measures
fluorescence at each interval and a derivative equation is used to
show a peak where the fluorescence drops off dramatically. This
uses the principle of SYBR as a double strand specific intercalating
dye.
9. There should be little or no reactivity in the NTCs, precise replicates, and
the melt curve analysis should show a single peak. If the melt curve shows
multiple peaks, new primers must be optimized and ordered.

Quantitative Real Time-PCR of Samples.
1. Once suitable primer pairs are found, use the same principles discussed
above in the Primer Optimization section to analyze expression of the
cDNA from the samples of interest that were reverse transcribed also
described above in the Reverse Transcription section.

Quantification and Statistical Analyses.
1. The slope of the line generated from plotting the threshold cycle (y-axis)
against the log ng RNA in the standard curve indicates the efficiency of
the reaction. In order to compare expression of 2 genes or to use a nonchanging internal control (e.g. 18S rRNA or 28S rRNA) for mathematical
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manipulations and determination of significance, the slopes must be within ±
0.1 of each other and have a R2-value of no less than 0.95.
a. A reaction that is 100% efficient will have a slope of -3.3, however
this is uncommon when using reverse transcriptase which is a very
inefficient reaction. Normally the slopes are less efficient, around 4.0 (~75%).
2. Using the equation of the best fit line, threshold cycles from samples can
be used to calculate how many log nanograms of RNA from the GOI are
present. The anti-log of this value is then taken to determine actual
nanograms of RNA.
3. The GOI value is then divided by the internal standard control (18S or
28S) and this gives the fold change in expression.
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Reagents.
1. Protein (Tissue) Resuspension Buffer (1L)
a. 85mM NaCl (4.97g)
b. 20mM KCl (1.49g)
c. 4mM MgCl (0.813g)
d. 0.2mM EGTA (0.076g)
e. 30mM Histidine (4.66g)
2. ATPase Buffer (1L)
a. 140mM NaCl (8.18g)
b. 20mM KCl (1.49g)
c. 3mM MgCl (0.61g)
d. 30mM Histidine (4.66g)
e. 3mM ATP (1.65g)
f. +/- 100uM Oubain
g. Filter Sterilize for longer shelf life
h. May change color, remake
3. Acid Molybdate Solution (100mL)
a. 0.5g Ammonium Molybdate in 0.5M H2SO4
b. If precipitate forms or color changes, remake
4. Saponin
a. Make 2mg/ml stock in water
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5. Coloring Agent (Fiske-Subbarow Reducer)
a. 5g in 31.5mL
b. Store in amber bottle (Foil tube) @ RT
c. Good for 1 month
6. Phosphate Standard Solution
a. 4mM phosphoric acid

Procedure.
1. Homogenize 20-30mg brain tissue in 1mL of cold protein resuspension
buffer by rotor-stator for 30-45secs. Place on ice.
2. Add 10uL of 2mg/ml saponin to 1mL of homogenate (final conc. =
20ug/uL), incubate @ 37C for 15min, and place on ice.
3. Run Bradford Assay and adjust protein concentrations accordingly with
protein resuspension buffer (minimum of 10mg/mL tissue weight or ~
1mg/mL protein).
4. In 96-well V-bottom plate, create standard curve with Phosphate Standard
Solution, making 7 2-fold dilutions beginning from 4mM (triplicates -- final
volume should be the same as protein sample wells).
5. Add 60uL of ATPase Buffer +/- oubain to wells in the same V-bottom plate
in step 4 for protein samples to be analyzed (triplicates for (-) oubain and
(+) oubain, therefore, you need six wells per sample).
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6. Add 5-10ug protein (50-100ug tissue weight) to wells, mix and incubate @
37C for 30min.
7. Add 120uL Acid Molybdate Solution to all wells, mix, then add 10uL of
Fiske-Subbarow Reducer, mix and incubate for 10min @ RT.
8. Centrifuge plate so that any precipitate is pelleted, and transfer 100uL to a
flat-bottom optically clear plate (not polypropylene).
9. Read spectrophotometrically at 660nm.
10. Use the equation of the line from the standard curve to convert OD to
concentration of phosphate (mM).
11. Subtract the +oubain values from the –oubain values, then use this
difference to calculate how much phosphate was generated specifically by
Na+/K+ ATPase.
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Mouse Neuroblastoma 2A (N2A) Maintenance.
1. Adherent N2A cells frozen in 95% complete media (Earl’s minimum
essentials medium (EMEM) + 10% heat inactivated fetal bovine serum
(FBS) + 1% penicillin/streptomycin solution (PS) with 5% DMSO are
rapidly thawed upon removal from nitrogen.
2. Cells are immediately placed into 20ml of warm complete medium in a
vented T-75 flask and allowed to incubate at 37°C until 90% confluent.
3. Cells should be passaged every 3-4 days by treatment with 0.25% (w/v)
Trypsin- 0.53 mM EDTA solution for 5 minutes and followed by scraping.
All traces of serum that contains trypsin inhibitor should be removed with a
PBS wash prior to adding trypsin-EDTA.
4. Cells in trypsin are then passaged to new flasks with 20ml of fresh
complete medium.

Differentiation of N2A Cells.
1. N2A cells can be treated with dibutyryl-cAMP to facilitate differentiation
from their oncogenic state to a neuronal state.
APPENDIX C: (CONTINUED)
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2. N2A cells are subcultured and added to 6 well plates at 50-60%
confluency (equivalent to 1 T-75 flask passaged to 3 6 well plates), and
are permitted to reattach overnight in complete medium.
3. Complete medium is then removed and cells are rinsed with PBS.
4. Dibutyryl cAMP (db-cAMP) is added at a concentration of 1mM to serumfree EMEM + PS, which is then applied to the cells in the 6 well plates.
5. These cells are then actively differentiating into neurons which is visible
under the microscope by the presence of extended neurites. This process
is allowed to continue for 48-72 hours.
6. These cells can then be treated with nerve growth factor (mouse maxillary
NGF-2S) by directly applying the NGF solution to a final in-well
concentration of 100nM.
7. After 1 hour, remove media from wells and rinse with PBS.
8. Add 350ul of RLT buffer with β-mercaptoethanol to the cells in each well,
scrape, and aspirate liquid into a Qiashredder tube.
9. Spin down at max speed for 3 minutes, remove Qiashredder from
collection tube and begin RNA isolation as described by the RNeasy
Qiagen protocol for animal cells. NGF elicits the induction of several
immediate early genes in differentiated Neuro2A cells as measured by
qRT-PCR (Figure 1).
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Preparation of 5mM Aβ Peptide Stock Solutions.
1. Recombinant amyloid peptide (1mg) purchased from rPeptide (Cat # A1002-2) is used to prepare monomeric, oligmeric and fibrillar forms of Aβ.
2. Using a Gastight Hamilton syringe, draw 221.7ul of cold 1,1,1,3,3,3
Hexafluoroisopropanol (HFIP) and puncture the rubber cap of the Aβ vial
to resuspend the powder.
3. Allow the solution to stand at room temperature for 30 minutes and
sonicate for 5 additional minutes.
4. Aliquot the suspension into microcentrifuge tubes (VWR # 20170-293), in
a 10ul (45ug) amount.
5. Allow the HFIP to evaporate overnight in a fume hood leaving only a thin
film of Aβ present at the bottom of the tube.
6. The next day, speedvac the tubes for 1 hour without heat to remove all
traces of liquid. These can be stored at -20°C on desiccant for several
months.
7. To use the Aβ right away, resuspend the 45ug film in 2ul of freshly opened
dry DMSO (Sigma # D2650) to yield a 5mM stock Aβ solution. Vortex
thoroughly and sonicate for 5 minutes.
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Preparation of Monomeric Aβ.
1. Dilute the 5mM Aβ DMSO stock with 98ul of water to yield a 100uM
preparation of monomeric Aβ. Then vortex and use.

Preparation of Oligomeric Aβ.
1. Dilute the 5mM Aβ DMSO stock with 98ul of ice cold phenol-free (phenolred-free) Ham’s F-12 culture medium to yield a 100uM preparation of
oligomeric Aβ.
2. Vortex and incubate overnight at 4°C. For optimal performance, this
should be used on the following day.

Preparation of Fibrillar Aβ.
1. Dilute the 5mM Aβ DMSO stock with 98ul of 10mM HCl to yield a 100uM
preparation of fibrillar Aβ.
2. Vortex and incubate overnight at 37°C.
3. The following day, neutralize acid with equimolar amount of NaOH. For
optimal performance, this should be used on the following day.
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FIGURE 1. Induced expression of IEGs in differentiated N2A cells by nerve
growth factor measured by qRT-PCR.
This figure shows NGF treated (gray bars) and non-treated (black bars)
db-cAMP differentiated Neuro2A expression (gray bars) as a percentage of
the average of undifferentiated Neuro2A cells (set as 100%) for the
immediate early genes (IEGs) Zif268, Arc, and Nur77. This figure
demonstrates that in Neuro2A cells differentiated for 72 hours with db-cAMP,
NGF causes a robust increase in IEG expression. Additionally, Na+/K
ATPase αIII expression, which is selectively over-expressed in neurons
compared to non-differentiated neuro2A cells, has increased expression in
the db-cAMP treated Neuro2A cells, quantitatively demonstrating that
differentiation of Neuro2A cells into neurons was being facilitated by the dbcAMP treatment. The values represented in this figure are the mean + SEM.
“*” indicates significant differences between db-cAMP differentiated Neuro2A
expression and undifferentiated Neuro2A (p < 0.05) when measured by oneway ANOVA. "†" above the bracket indicates differences (P < 0.05) in
expression between NGF-treated db-cAMP differentiated Neuro2A cells and
non-treated db-cAMP differentiated Neuro2A cells.
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